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Abstract 
 
 Extracellular vesicles play important and crucial roles in orchestrating and modulating 
cellular responses under both normal and diseased conditions. In my thesis work, I studied 
extracellular vesicle release from astrocytes during CNS inflammation. Moreover, I studied how 
extracellular vesicles can modulate and drive the immune response during active CNS disease. 
Extracellular vesicles encompass a heterogeneous group of cell-derived vesicles that have been 
found to be important in initiating and directing pathological responses. 
 In my thesis work, I focused on the characterization and quantification of extracellular 
vesicles from astrocytes under normal and inflammatory conditions. As described in chapter three 
of my thesis, I developed a semi-quantitative flow cytometry method for analysis of extracellular 
vesicles from astrocytes and found that following cytokine challenge in vitro, astrocytes releases 
more extracellular vesicles. Additionally, I studied whether astrocyte-derived extracellular 
vesicles could be detected in peripheral circulation and if their numbers increased in a mouse-
model of multiple sclerosis. Allowing for the potential of astrocyte-derived extracellular vesicles 
to be potent biomarkers to monitor disease progression. 
 Furthermore, I studied whether extracellular vesicles could modulate the immune system 
during active disease. As described in chapter four, I found that injection of plasma extracellular 
vesicles into animals during the height of clinical disease in a mouse model of multiple sclerosis 
induced a relapsing-remitting phenotype that seemed to be driven by an unidentified interaction  
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between the blood coagulation factor fibrinogen and CD8+ T cells. Additionally, post-translational 
modifications analysis of the proteomic content of plasma extracellular vesicles identified 
extensive citrullination occurs on proteins in blood plasma that may be causative in driving the 
immune responses observed. 
 In general, my thesis studies focused on the characterization and effect of extracellular 
vesicles from a CNS-cell source and in an animal model of multiple sclerosis. 
       
i 
Role of Extracellular Vesicles on Immune Regulation in an Animal Model of Multiple Sclerosis 
 
 
Cory Michael Willis 
BSc, University of Pittsburgh, 2012 
 
 
 
 
 
 
 
 
 
 
 
 
A Dissertation 
Submitted in Partial Fulfillment of the 
Requirements for the Degree of  
Doctor of Philosophy 
at the 
University of Connecticut  
 
2019 
 
ii 
 
 
 
 
 
 
 
 
 
Copyright by 
Cory Michael Willis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2019
iii 
APPROVAL PAGE 
 
Doctor of Philosophy Dissertation 
 
Role of Extracellular Vesicles on Immune Regulation in an Animal Model of Multiple Sclerosis 
 
Presented by 
 
Cory Michael Willis, BSc 
 
 
 
Major Advisor 
___________________________________________________________________ 
     Stephen J. Crocker, Ph.D. 
 
Associate Advisor 
___________________________________________________________________ 
     Kyle Baumbauer, Ph.D. 
 
Associate Advisor 
___________________________________________________________________ 
     Royce Mohan, Ph.D. 
 
Associate Advisor 
___________________________________________________________________ 
     Robert Clark, M.D. 
 
 
 
 
 
 
 
 
 
 
 
University of Connecticut 
 
2019 
iv 
Acknowledgements 
            I want to first express my sincerest gratitude and immense appreciation to my mentor Dr. 
Stephen Crocker for his continuous support of my graduate education and training over the last 
five and a half years. His patience, motivation, and knowledge (which extends outside the realm 
of academia) has helped me develop into a well-rounded, independent scientist. His open-door 
policy, which I contend was not his official stance when dealing with me, allowed for innumerable 
opportunities with which to discuss new experiments and out-of-the box ideas. His support of my 
insatiable curiosity, even if it came at inopportune times, about the fascinating world of glial 
biology fostered my deep-appreciation for the complexities of glia and a passion to explore the 
many unanswered questions. I am grateful for Steve as a mentor, friend, and now colleague as I 
begin to transition from graduate student to post-doctoral fellow. Without his guidance and support 
through the rare highs and numerous lows of graduate school, I would not have been as 
accomplished and prepared as I begin the next stages of my career. 
 Besides my advisor I would also like to thank members of my thesis committee: Drs. Kyle 
Baumbauer, Royce Mohan, and Robert Clark for their insightful comments and encouragement 
throughout my studies. They asked the hard questions that allowed me to widen and look at my 
research from different perspectives. 
            I want to thank my past and present “pod”-mates, as well as the seemingly unending string 
of rotation and summer students, for helping me scientifically and providing a fun and entertaining 
work environment over my time as a graduate student. These include, but are not limited to, Dr. 
Alexandra Nicaise, Dr. Kasey Johnson, Erin Banda, Anthony Sacino, Xiufang Liu, Sangita Karki, 
Maddie Youngstrom, Dr. Rachel Koski, Rob Pijewski, and Pearl Sutter.
v 
         I would also like to thank all the close friends I have made during this time, especially Cara 
Hardy, Brittany Knight, Cory Brennick, and Carissa Sirois who were always there to talk after a 
rough day in lab and were sources of confidence to continue working through my degree. I am 
particularly grateful to Alexandra Nicaise for her unwavering support and patience with the 
successes and disappointments that come with science. She has been nothing but enthusiastic in 
her encouragement of my work. 
 Last but not least, I would like to thank my family and friends who have been supportive 
throughout this process, especially my parents who have always pushed the importance of 
education. I would also like to personally thank Dr. Evan Jellison at the flow cytometry core and 
Maya Yankova at the electron microscopy core. Without their patience (which cannot be 
expressed in words, rather sainthood), support, and knowledge I would not have been able to 
complete even half of my thesis work. You both truly hold a special place in my heart.   
  
vi 
Table of Contents 
 
Chapter 1: 1 
Multiple Sclerosis 
I. History of Multiple Sclerosis 1 
II. Prevalence and Risk Factors 2 
III. Diagnosis and Clinical Forms of Multiple Sclerosis 4 
IV. Pathogenesis of Multiple Sclerosis 15 
V. Immune System in Multiple Sclerosis 21 
VI. Role of Astrocytes in Multiple Sclerosis 24 
VII. Animal Models of CNS demyelination 34 
VIII. Current Disease Modifying Therapies and Future Strategies 37  
Chapter 2: 41 
Extracellular Vesicles 
I. Brief History of Extracellular Vesicles 41 
II. Extracellular Vesicle Subtypes 42 
III. Extracellular Vesicle Biogenesis and Release 45 
IV. Extracellular Vesicles and Neurodegenerative Diseases 52 
V. Extracellular Vesicles as Biomarkers in Neurodegenerative Diseases 57 
Chapter 3: 62 
A Refined Bead-free Method to Identify Astrocytic Exosomes in Primary Glial Cultures 
and Blood Plasma 
I. Abstract 63
vii 
II. Introduction 64 
III. Materials and Methods 66 
IV. Results 70 
V. Discussion 75 
VI. Figures 81 
Chapter 4: 88 
Extracellular Vesicle Fibrinogen Induces Encephalitogenic CD8+ T cells in a Mouse Model 
of Multiple Sclerosis 
I. Abstract 89 
II. Introduction 90 
III. Materials and Methods 91 
IV. Results 99 
V. Discussion 102 
VI. Acknowledgements 107 
VII. Figures 108 
Chapter 5: 116 
Discussion and Future Directions 
I. Astrocytes and Exosomes 116 
II. Plasma EVs and Relapsing-Remitting Multiple Sclerosis 122 
III. Concluding Statement 127 
 
Bibliography 132 
viii 
List of Figures and Tables 
 
Chapter 1: 1 
Multiple Sclerosis 
Figure 1-1: Clinical disease course in the different types of multiple sclerosis 11 
Figure 1-2: Expanded disability status score for monitoring multiple sclerosis  
disease progression 13 
Table 1-1: Multiple Sclerosis Lesion types and associated pathology 20 
Figure 1-3: Astrocyte endfoot processes form the glia limitans as part of the  
neurovascular unit 30 
Figure 1-4: Categorization of reactive astrocyte phenotypes lies on a spectrum 32 
 
Chapter 2: 41 
Extracellular Vesicles 
Figure 2-1: Molecular Machineries involved in EV biogenesis and release 50 
 
Chapter 3: 62 
A Refined Bead-free Method to Identify Astrocytic Exosomes in Primary Glial Cultures 
and Blood Plasma 
Figure 3-1: Identification and characterization of a flow cytometry methodology 
to identify astrocytic exosomes in media from primary astrocyte cultures 81 
Figure 3-2: Quantitative increase in detection of astrocytic exosomes in media  
from primary astrocyte cultures following treatment with IL-1β 83 
ix 
Figure 3-3: Identification and characterization of astrocyte-derived exosomes in  
blood plasma from mice and increased detection of GFAP+ exosomes in blood  
from mice during EAE 85 
 
Chapter 4: 88 
Extracellular Vesicle Fibrinogen Induces Encephalitogenic CD8+ T cells in a Mouse Model 
of Multiple Sclerosis 
Figure 4-1: pEVs induced a spontaneous relapsing-remitting phenotype in 
wild-type C57BL/6 mice during MOG35-55-induced EAE. 108 
Figure 4-2: pEVs induce a CD8+ T-cell response responsible for the 
development of a spontaneous relapsing phenotype in MOG35-55-EAE 110 
Figure 4-3: pEV fibrinogen is necessary to induce a spontaneous 
relapsing-remitting phenotype in wild-type C57BL/6 mice during 
MOG35-55-induced EAE 112 
Figure 4-4: Proteomic analysis of pEVs from RRMS patient samples 
identified a unique citrullination peptide motif. 114 
 
Chapter 5: 116 
Discussion and Future Directions 
Figure 5-1: Astrocyte EVs promote the differentiation and maturation 
of rOPCs in vitro 128 
Figure 5-2: IVIS imaging of DiR-labeled EVs injected into naïve and 
MOG-EAE mice 130 
x 
List of Abbreviations 
ACR: acute cytokine response 
ADEM: acute disseminated encephalomyelitis 
AD: Alzheimer’s disease 
ALS: amyotrophic lateral sclerosis 
APC: antigen presenting cell 
aEV: astrocyte extracellular vesicle 
BBB: blood-brain-barrier 
BDNF: brain-derived neurotrophic factor 
BMVEC: brain microvascular endothelial cell 
CNS: central nervous system 
CSF: cerebrospinal fluid 
CIS: clinically isolated syndrome 
CyTOF: cytometry by time of flight 
DMT: disease modifying therapy 
ESCRT: endosomal sorting complex required for transport 
EEV: endothelial extracellular vesicle 
EDSS: expanded disability status scale 
EAE: experimental autoimmune encephalomyelitis 
EV: extracellular vesicle 
FACS: fluorescence-assisted cell sorting 
FDA: food and drug administration 
GFAP: glial fibrillary acidic protein
xi 
HD: Huntington’s disease 
ILV: intraluminal vesicle 
IV: intravenous 
LINGO: leucine-rich repeat and immunoglobulin-like domain-containing protein 
MP: microparticle 
MV: microvesicle 
MRI: magnetic resonance imaging 
MS: multiple sclerosis 
MVB: multivesicular body 
MBP: myelin basic protein 
NMO: neuromyelitis optica 
NAWM: normal-appearing white matter 
OCB: oligoclonal bands 
PD: Parkinson’s disease 
PNS: peripheral nervous system 
pEV: plasma extracellular vesicle 
PPMS: primary progressive multiple sclerosis 
PLP: proteolipid protein 
PPMS: primary progressive multiple sclerosis 
rOPC: rat oligodendrocyte progenitor cell 
ROS: reactive oxygen species  
RRMS: relapsing-remitting multiple sclerosis 
SPMS: secondary-progressive multiple sclerosis
xii 
SILAC: stable isotope labeling with amino acids in cell culture 
SOD1: superoxide dismutase 1 
TEM: transmission electron microscopy
 1 
Chapter 1. Multiple Sclerosis 
 
I. History of Multiple Sclerosis  
 Through retrospective analysis of historical medical records, the first observed cases of MS 
may have occurred as early as the 14th century (1), and the first definitive case was thought to have 
affected Sir Augustus D’Esté, the illegitimate grandson of George III, who chronicled the disease 
in his diary from its initial onset in 1822 to his death in 1848 (2, 3). While it is possible that MS 
was a relatively uncommon disease before this time, the more likely explanation is that difficulty 
in differentiating MS from other contemporary neurological disorders, including neurosyphilis and 
paralysis agitans, may have resulted in a delay in a formal description of MS from appearing in 
the literature before the early 19th century.  
 Credit for the initial documentation of the clinical features of MS is usually attributed to 
Cruveilhier, a Parisian anatomist, in 1841 or 18421. It was not until 1868 that Jean-Martin Charcot 
provided the first, detailed descriptions of the clinical manifestations of MS, established criteria 
for its diagnosis, and, for the first time, correlated clinical symptoms with pathological changes: 
“Multiple sclerosis is reduced simply to a contracture of the lower extremities, with or 
without any spasticity in the upper extremities…In cases of this kind, the present or past 
coexistence of some of the cephalic symptoms such as nystagmus, diplopia, disturbances 
of speech, dizziness, apoplectiform attacks, special mental symptoms, alone can provide 
the basis for a decisive diagnosis. The spinal form of the disease is far from 
rare…incidence of the disease will tend to increase as its diagnosis reaches a higher level 
of accuracy2.”  
                                                
1 Cruveilhier J. Anatomie pathologique de corps humain ou descriptions avec figures lithographiees et coloriees des 
diverses altrnations morbides don’t le corps humain est susceptible. Paris, France: Bailliere; 1829-1842 
2 Charcot JM. Expose des titres scientifiques. Paris, France: Victor Goupy et Jourdan; 1883. 
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 Over the next 150 years, ideas on the cause and pathogenesis of this disease have developed 
the basis for studies on the epidemiology, genetics, pathology, immunology, and neurobiology of 
MS. This has moved the study of MS from a system based on exploratory approaches into a 
productive discipline grounded in experimental and evidence-based science. As a result, new 
questions relating to the definition, nosology, cause, mechanisms, and management of the disease 
now challenge several long-standing concepts about this disease. 
 
II. Prevalence and Risk Factors 
 Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS). It is the most common cause of neurological disability in young and 
middle-aged adults (4). The incidence of MS is low in childhood and increases with age peaking 
between 20 and 40 years of age. There are an estimated 2.3 million people worldwide currently 
living with MS (5), however, this number probably underestimates the true global total as 
preliminary results from a study by the United States National MS Society on the prevalence of 
MS estimate nearly 1 million people in the United states alone are currently living with the disease. 
Women have universally been found to be disproportionately affected by the disease, with the MS 
prevalence ratio of women to men having markedly increased during the last 100 years (2.3-3.5:1), 
indicating a true increase in MS among women but not men (6-9). It has been posited that this 
rapid increase probably reflects some yet unidentified changes in the environment or nutrition (10). 
However, despite the effect of sex on the prevalence of MS globally, the effect on the clinical 
features of MS is not as clear. There is evidence that, in general, women have an earlier onset of 
the disease by approximately 2-5 years, a slightly decreased prevalence of being affected by the 
primary progressive disease course, and have reduced progression towards disability than men (11, 
12).  
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 The cause of MS is unknown but current evidence points to an interaction between 
environmental and genetic factors in the development of the disease. The timing of exposure to 
environmental factors plays a significant role, with childhood and adolescence being the most 
critical time frames (13-15). Evidence for these susceptibility time windows comes from elegant 
longitudinal migration studies between high- and low-risk regions. Migrants who have been found 
to immigrate from a low-risk to high-risk region prior to adolescence adopt the risk of their new 
region, whereas migrants who immigrated after adolescence retained the risk of their home region 
(16, 17). However, the precise age range cutoff is less clear and the risk of exposure could span a 
wider range than was initially thought (18).  
 Environmental factors known to increase the risk of developing MS encompass (1) 
geography, (2) exposure to infectious agents, and (3) gestational environment. Evidence has 
pointed to a significant role of the latitude, i.e. increasing distance north or south of the equator, 
with an increased incidence and prevalence of MS, however this correlation has been found to be 
decreased over the past decades (19-21). There has been no study that has directly and conclusively 
linked a single causative infectious agent to the development of MS. In fact, it is thought that MS 
can be triggered by several microorganisms in genetically susceptible patients. For example, >99% 
of MS patients are seropositive for Epstein-Barr virus compared to 95% in the general population, 
and patients with a history of infectious mononucleosis have a higher risk of developing MS 
compared to uninfected individuals (12, 22). Lastly, the risk of MS in the northern hemisphere has 
been found to depend on the month of birth, with the highest risk for individuals born in May and 
the lowest for those born in November (17), which has also been found in animal models of the 
disease (23).  
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 While MS does not have a definitive genetic cause, numerous single nucleotide 
polymorphisms have been associated with its development (24). Studies on the contribution of 
genetics to the risk of developing MS have examined heritability within families and determined 
that risk is lower than would be expected for a genetically inherited disease. MS has been found 
to have an overall familial recurrence rate of 20% and shown a concordance rate in monzygotic 
twins in 24-30% of cases compared to 3-5% in dizygotic twins. Furthermore, there is no increased 
risk for adoptive relatives and besides kinship, the sex of the affected family member and a parent-
of-origin effect is also known to influence MS risk (25, 26). Given the extensive investigation into 
finding a genetic cause for MS, current evidence now points to no marked role for classic genetic 
associations with MS. Stronger evidence points to environmental factors as a major driver of 
disease susceptibility, opening up the possibility of epigenetics (which some people incorrectly 
call “genetics”) as a source of risk for MS (27). 
 
III. Diagnosis and Clinical Forms of Multiple Sclerosis 
 The diagnosis of MS has traditionally relied upon clinical indicators that have been 
developed over decades clinical evidence for associations with MS. The mainstay triad of clinical 
tests used for MS diagnosis are MRI, oligoclonal bands in cerebrospinal fluid (OCBs), and clinical 
disability. These tests also have a temporal component that is required for the diagnosis of MS. 
For instance, brain imaging that identifies white matter lesions must also change in space and time 
to support a diagnosis of MS but can also help to eliminate alternative diagnoses that can present 
like MS. The most commonly used standard for the determination of a diagnosis of MS is based 
on the McDonald Criteria developed in 2001 by the International Panel on the Diagnosis of MS 
(28). This was the first formal review of the criteria for MS diagnosis since 1982 (29) and was 
developed to facilitate the diagnosis of MS in patients with a variety of presentations, including 
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“monosymptomatic” disease suggestive of MS, disease with a typical relapsing-remitting course, 
and disease with insidious progression, without clear attacks and remissions. Previously used terms 
in the diagnosis of MS such as “clinically definite” and “probable MS” were replaced with MS, 
“possible MS”, or “not MS”. The McDonald Criteria is routinely updated to keep pace with 
scientific discoveries and advances in medicine. 
 Despite the development of an internationally-recognized standard of criteria for the 
diagnosis of MS, the focus on the clinical and supporting laboratory evidence from patients that 
establishes the diagnosis remains dissemination of sclerotic plaques in both space and time—
disease-related changes have effected multiple regions of the CNS, including the white and gray 
matter, brain stem, spinal cord, and optic nerve to form the cornerstone of diagnosis of the disease 
(30, 31). The overwhelming majority of patients who develop MS begin with a single episode, 
termed CIS. The initial episode tends to involve the optic nerve, brain stem, or spinal cord and 
resolve over time. Clinically isolated syndrome is defined as a monophasic clinical episode 
evidenced by patient-reported symptoms and objective findings reflecting a focal or multifocal 
inflammatory demyelinating event in the CNS, which develops acutely or sub-acutely, with a 
duration of at least 24 hours, with or without recover, and in the absence of fever or infection; 
similar to a typical MS relapse (attack and exacerbation) (32-34). The concept of CIS is well-
established in the field and is currently being incorporated into the WHO International 
Classification of Disease, version 11 (33, 35). However, not all CIS patients develop MS. For 
example, patients experiencing a monophasic, idiopathic inflammatory demyelinating disease that 
has all the tell-tale signs of CIS and/or MS, cannot be readily distinguished from patients with 
ADEM (36). Therefore, consistent monitoring for emergence of new or exacerbation of existing 
symptoms with routine examinations of the CNS for de novo lesion development are vital for a 
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diagnosis of MS. If the patient is subsequently diagnosed with MS by fulfilling the diagnostic 
requirement of dissemination of plaques in space and time, and ruling out other diagnoses, the 
clinically isolated syndrome was that patient’s first attack. 
 Following the initial attack that brings the patient into the clinic for examination, 
monitoring the progression of the disease through MRI scans, oligoclonal analysis, and routine 
follow-up examinations by a clinician allows for the establishment of dissemination in time and 
place of lesions, detection of inflammatory status, and the development or worsening of clinical 
symptoms, respectively. MRI is routinely used to identify the development of new lesions in 
patients. That is, episodes affecting separate sites within the CNS have occurred at last 30 days 
apart. To determine dissemination in time of magnetic resonance lesions requires one gadolinium-
enhancing lesion at least three months after the onset of the clinical event; or a new T2 lesion 
compared with a reference scan done at least 30 days after the onset of the clinical event. 
Intravenous gadolinium injection during an MRI scan serves two practical purposes: (1) determine 
blood-brain-barrier permeability as a result of CNS damage because under normal, non-disease 
conditions gadolinium has significantly lower permeability, and (2) gadolinium incorporates into 
CNS lesions and provides enhanced contrast indicative of an area of active MS-related 
inflammation, meaning demyelination has occurred within the last two or three months. 
Longitudinal studies of MRI scans of patients with an initial diagnosis of CIS are predictive for 
the development of MS (37).  
 Oligoclonal bands are an additional way to help narrow down the diagnosis of MS. 
Excluding the use of MRI in the diagnosis of MS, the single most consistent laboratory  diagnostic 
tool used to qualify MS is increased oligoclonal immunoglobulins in the CSF (38). Clonal 
expansion of immunoglobulin-secreting B cells and plasma cells in the CNS results in the 
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characteristic finding of CSF-specific OCBs, which are bands of immunoglobulins that have been 
identified in MS patients (39). Normally, only OCBs made of immunoglobulin G antibodies are 
considered, though sometimes other proteins can be taken into account (40-42). Up to 95% of all 
patients with MS have permanently observable OCBs (43). In patients with a single demyelinating 
episode, detection of intrathecal immunoglobulin synthesis may predict progression to MS (44), 
and oligoclonal bands in CSF during the early phase of disease are often associated with a 
worsened outcome (45). Although the targets of these immunoglobulins are probably multifaceted, 
their presence implies a CNS-restricted immune response. However, some argue that the 
specificity of OCBs for MS is poor due, partially, because infections can cause a similar banding 
pattern (31). Therefore, a need to identify bonafide biomarkers to track disease initiation and 
progression will afford clinicians the ability to therapeutically monitor and target disease activity 
and responses to therapies. 
 MS patients often present with heterogeneous clinical manifestations involving the motor 
(i.e., walking difficulties), sensory (i.e., numbness or tingling in various parts of the body), visual 
(i.e., blurred and/or double vision), and autonomic systems (i.e., urinary symptoms), and the vast 
majority of patients will develop progressive decline in functions associated with speaking, 
swallowing, movement, and cognitive faculties. The disease course of any given MS patient is 
often unique and highly variable. Despite extensive scientific investigation into the root cause of 
MS, no known singular cause of MS has been identified. MS is currently incurable.   
 The clinical course of MS is unpredictable, varied, and individualized, but dependent on 
the type of disease. Patient’s given an initial diagnosis of CIS who then experience at least two 
additional relapses are described as having RRMS. RRMS is the most common form of MS, 
affecting approximately 85% of people with MS, that is broadly comprised of three stages: (1) pre-
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clinical, (2) relapsing-remitting, and (3) progressive (Figure 1-1A). The initial, pre-clinical stage, 
wherein an unknown combination of the previously mentioned environmental and genetic risk 
factors trigger the disease, prompts a visit to the clinic.  
 Patient’s given the initial diagnosis of CIS who then experience at least two additional 
relapses are described as having RRMS. Relapses are defined as newly appearing neurological 
symptoms that occur in the absence of fever or infections and last for more than 24 hours with 
symptoms present over a period of a few days that then spontaneously resolve within a few weeks. 
The relapsing-remitting disease phenotype can reoccur every few weeks, months, or even years, 
but is highly variable from patient to patient. During the RRMS clinical stage, the accumulation 
of these discrete, self-limited episodes (i.e., relapses) can lead to extensive and persistent residual 
neurologic dysfunction, such as sensory disturbances, optic neuritis, or disturbances in motor and 
cerebellar function. Disability is commonly measured using the Expanded Disability Status Scale 
(EDSS) (Figure 1-2). This inflammatory stage may begin sub-clinically and only be evident 
through gadolinium-enhanced MRI imaging for active lesions.  
 Following years or decades of relapsing-remitting episodes and accumulating lesion load 
can lead to the progressive clinical stage of the disease wherein neurologic dysfunction 
progressively worsens leading to permanent neurological deficits such as: cognitive impairment, 
depression, emotional lability, dysarthria, dysphagia, vertigo, progressive quadriparesis, sensory 
loss, ataxic tremors, pain, sexual dysfunction, spasticity, etc (46). This is defined as the secondary-
progressive form of the disease and can present with or without super-imposed relapses (Figure 
1-1B). Studies (47) have reported on a wide range of the percentage of patients that transition to 
this form of the disease, from as high as 70-75% (46, 48) to as low as between 15% (49) and 30% 
over long-term follow-ups (35). The latter percentages are lower than previously reported and 
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could reflect changes in the natural history of the disease and the effect of disease-modifying 
treatments. 
 In 15% of MS patients, their disease is progressive from the outset and is therefore termed 
PPMS (12, 50). PPMS is described as a gradual but progressively declining clinical course without 
the presence of disease remittance (12, 50) (Figure 1-1C). However, 40% of patients experience 
superimposed relapses, similar to what is observed in patients with SPMS (51). Patients typically 
present with symptoms in their 40s, and there is currently no evidence of gender playing a role in 
the incidence rate between men and women. Clinical symptoms tend to be dominated by 
dysfunctions of the corticospinal tracts, which leads to patients often presenting with upper motor 
neuron syndrome of the legs that gradually worsens to quadriparesis (12, 46). Additionally, 
cognitive decline, visual loss, brain-stem syndromes, cerebellar dysfunction, bowel and bladder 
dysfunction, and sexual dysfunction are common clinical symptoms associated with the disease 
(46). The disease course of PPMS is more aggressive and severe than RRMS. As an example, 
using the EDSS score of 6, which would indicate the need for unilateral support to walk at least 
100 m, is reached in 7 years in PPMS patients compared to 12 years in SPMS patients (48). Despite 
these clinical findings, further exploration of the two-forms of progressive MS (PPMS and SPMS) 
have been found to be more similar than different—i.e., the differences between them are relative 
rather than absolute (52). Moreover, current pathological data suggest the immune system is only 
weakly involved in PPMS which is supported by the wealth of clinical data demonstrating that 
PPMS patients do not measurably benefit from any current disease-modifying therapies available 
to RRMS patients. PPMS will not be extensively covered throughout the course of this thesis, 
instead my focus will remain on the study of relapsing-remitting disease. 
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 The standardized definitions of the clinical courses of MS—relapsing-remitting, primary 
progressive, and secondary progressive—were proposed in 1996 (51). Despite this, these 
definitions are purely descriptive in terms of clinical presentation, incidence rate, and course of 
the disease and do not provide any meaningful information or correlation with any underlying 
pathophysiology of the disease. Since the standardized definitions have been accepted, the 
terminology has evolved to describe the presence or absence of activity, including relapses and 
progression and, on MRI, new lesions indicating inflammatory activity and atrophy, which 
suggests ongoing neurodegeneration. Being able to link the phenotype of the disease firmly to the 
pathophysiology will be crucial for identifying new therapeutic targets for drug discovery to aid 
patients with the disease. 
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Figure 1-1: Clinical disease course in the different types of multiple sclerosis. Representative 
graphs of clinical presentations of the different types of MS. Y axis depicting increasing disability; 
X axis representing time. (A) Relapsing-remitting multiple sclerosis clinical disease course. (B) 
Secondary-progressive multiple sclerosis clinical disease course. (C) Primary-progressive 
multiple sclerosis clinical disease course. Figure adapted from the National Multiple Sclerosis 
Society: www.nationalmssociety.org/What-is-MS/Types-of-MS 
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Figure 1-2: Expanded disability status score for monitoring multiple sclerosis disease 
progression. The EDSS was developed by neurologist John Kurtzke as a method of quantifying 
neurologic impairment in multiple sclerosis and monitoring changes in the level of disability over 
time (53). The scale is widely used in clinical trials and in the assessment of people with multiple 
sclerosis (54). Figure is from Singh et al, 2012 (55).  
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IV. Pathogenesis of Multiple Sclerosis  
 The diagnostic hallmark of demyelinating diseases, most notably in MS, is the 
development and appearance of sclerotic demyelinated plaques (i.e., lesions) in the white and gray 
matter. Four neuropathological patterns of active lesions (e.g., type I-IV) have been described for 
MS (Table 1-1) based on the presence or absence of complement and immunoglobulins, apoptotic 
nuclei, and/or preferential loss of myelin protein (56), which give rise to the four main types of 
MS lesions: (1) reactive, (2) active demyelinating, (3) chronic active, and (4) chronic inactive. 
Briefly, reactive and active demyelinating plaques are described as containing dense infiltrates of 
macrophages that contain myelin proteins and are predominately identified in the early stages of 
the disease. Chronic active plaques tend to have an inactive core with little to no macrophage 
infiltration but are surrounded on the perimeter by active macrophages. Finally, chronic inactive 
plaques have little to no macrophage infiltration in the entirety of the plaque. The emergence of 
these lesions often has a propensity for certain regions of the CNS including: optic nerves, 
periventricular white matter, brain stem, cerebellum, and spinal cord (46, 57). It has been noted 
that while the predominant type of lesion in a patient may evolve over time (i.e from active to 
chronic inactive) that the pattern of all lesions in a patient at any one time are consistently of the 
same classification. The development of lesions in MS can be viewed as the end-stage of a complex 
process of inflammation, demyelination and remyelination, astrogliosis, and axonal damage and 
degeneration. However, despite extensive studies on the pathology of MS lesions, the order of 
events as they relate to lesion formation remain elusive. What is known is that CNS tissue damage 
in MS is a result of a complex and dynamic interplay between the body’s immune system and 
resident CNS cells including, astrocytes, microglia, oligodendrocytes, and neurons.  
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 There is debate, however, on whether the root cause of MS is extrinsic or intrinsic to the 
CNS, i.e., the inside-out (58, 59) or outside-in (60, 61) hypotheses that have dominated the debate 
for decades. The “inside-out” hypothesis is based on pathological analysis of the brains of MS 
patients which has revealed oligodendrocyte loss and myelin defects and damage without the 
presence of active inflammation. The initial event could be the result of oligodendrocyte apoptosis, 
through a yet unidentified process or through a viral infection that could cause CNS tissue damage 
(30, 62). This loss of oligodendrocytes and generation of myelin debris then results in the 
generation of antigens against myelin epitopes and leads to a secondary inflammatory event that 
results in further demyelination (58, 59, 63). This is not to be confused with leukodystrophies, 
which are a rare group of progressive genetic diseases that leads to abnormal development or 
destruction of the white matter (64). The opposing hypothesis of “outside-in” argues the 
pathogenesis of MS is centered on the idea that dysregulation of the immune system leads to the 
generation of autoreactive cells against components of the myelin-sheath. For example, BBB 
disruption can lead to the leakage of the blood-plasma factor fibrinogen into the CNS parenchyma 
where it is deposited as insoluble fibrin, which leads to the exposure of cryptic epitopes that can 
potently activate the innate immune system (65, 66). In fact, in both MS and EAE, robust fibrin 
deposition and microglial activation are observed in the white matter (67), which could act to drive 
the necessary signals for CNS-specific T cell infiltration that results in the characteristic formation 
of lesions with active inflammation and demyelination (60, 61). 
 The most salient features of the MS disease pathology are the selective and primary 
destruction and loss of oligodendrocytes, axonal degeneration, BBB breakdown, multifocal 
inflammation, demyelination, and reactive gliosis (35, 68-70). Although myelin is almost 
completely lost in MS lesions, disruption and loss of neuronal integrity (i.e., neurodegeneration) 
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is particularly relevant because it is considered the main underlying mechanism of permanent 
clinical disability due to the acute loss of axons in new inflammatory lesions in MS patients, which 
continues, albeit more slowly, over time in chronically demyelinated lesions (35). Although, it 
should be noted that axonal destruction is variable from patient to patient and even between lesions 
in the same patient (71, 72).  
 The formation of lesions is known to occur as a result of inflammation consisting of T 
lymphocytes, B lymphocytes, and plasma cells (e.g., macrophages and neutrophils) (30, 31, 35). 
Post-capillary venules and veins serve as the initial site for the inflammatory reaction (Charcot 
1880), which results in perivenous demyelination that is observed in the initial stages of the 
disease. As a result, these lesions then “fuse” to already established demyelinated plaques causing 
the lesion border to expand into the surrounding NAWM3. These pathological patterns were first 
noted in 1916 by Dr. James Walker Dawson while performing autopsies of brains of people with 
MS. These typical perivenous extensions of established lesions have now been retroactively 
described as Dawson’s fingers and correlate with a diagnosis of MS (73, 74). The demyelinating 
process is also associated with the activation of astrocytes and microglia during active tissue injury, 
which results in the formation of gliotic scars (75, 76), which will be covered in detail further on. 
MS lesions can, in part, become remyelinated through the recruitment of oligodendrocyte 
progenitor cells (OPCs) to the site of injury (58). Areas that have been remyelinated are termed 
shadow plaques, which are sharply demarcated inactive lesions that present with axons ensheathed 
in uniformly thin myelin (77). However, the extent to which this recovery occurs is highly variable 
from lesion to lesion and is considered incomplete (78). Similar perivenous and confluent 
demyelinated lesion formation have also been identified in the gray matter of brains of MS patients, 
                                                
3 Dawson J.W. (1916). “The histology of disseminated sclerosis”. Trans. R. Sco. Edinb. 50: 517-540. 
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including the cerebral and cerebellar cortex (79, 80), the deep brain stem nuclei (81-83), and the 
gray matter of the spinal cord (84).  
 During the progressive phase of the disease, the contribution of the peripheral immune 
system decreases and immune responses are thought to be confined to the CNS compartment. It is 
also during this advanced stage of the disease where the CNS pathology markedly changes from a 
focal to diffuse white matter injury, which is associated with wide-spread microglial activation, 
diffuse lymphocytic and monocytic infiltrates (75), and increasing cortical involvement. The latter 
is thought to be associated with the de novo development of ectopic lymphoid-like follicles in the 
meninges (85). These lymphoid-like follicles have been found to contain B cells, T cells, and 
plasma cells, with intrameningeal follicles showing robust B cell proliferation (86). The formation 
of these meningeal lymphoid follicles in MS patients could represent a critical step towards the 
maintenance of humoral autoimmunity and in disease exacerbation, which has led to the targeting 
of B cells as an emerging therapeutic target in this stage of the disease (87). In addition, in the 
cerebral cortex, widespread subpial cortical demyelination is present and active subpial 
demyelination is oriented toward inflammatory infiltrates in the leptomeninges (75, 88). 
Inflammation in and around MS lesions is seen in all stages of the disease, thus being present not 
only in the brain of patients who died in early (relapsing) MS but also in primary or secondary 
progressive MS (89). However, in the progressive forms of the disease, diffuse tissue injury is also 
caused by mechanisms other than the compartmentalized immune response, including 
degeneration of chronically demyelinated axons (90), damage and dysfunction of astrocytes (91, 
92), and microglia activation (93).  
 The selective perivenous and confluent primary demyelination with oligodendrocyte loss 
distinguishes MS from other disease with focal white and gray matter lesions. As examples, NMO, 
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focal demyelinated lesions with severe axonal destruction follow a primary astrocyte damage 
triggered by specific antibodies against aquaporin-4 (94). In other inflammatory conditions, 
primary demyelination may follow virus infection of oligodendrocytes (e.g., progressive 
multifocal leukoencephalopathy). In this situation, demyelination initially affects the territories of 
single oligodendrocytes, but does not reflect the MS typical perivenous pattern (95). Focal white 
matter lesions in other inflammatory diseases or stroke are mainly destructive with parallel loss of 
myelin, oligodendrocytes, and axons. 
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Table 1-1: Multiple Sclerosis Lesion types and associated pathology. Adapted from (57)  
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V. Immune System in Multiple Sclerosis 
 It is widely accepted that in most forms of MS there is significant involvement of the 
immune system as both an initiator of disease and a driver of the clinical relapses in the earliest 
stages. Studies utilizing mice and marmoset animal models of disease, particularly EAE, have 
identified a fundamental role for the adaptive arm of the immune system in the development of 
autoimmunity and the pathogenesis of EAE (96, 97). This has translated to MS patients, as 
numerous genetic and pathological analyses of MS lesions and immune cells—i.e. T cells and B 
cells—and their products in the blood and CSF of patients has corroborated the findings in lower 
vertebrates and has led to the success of clinical trials in MS that target immune molecules or 
specific cell types (31, 96, 98, 99). This has reinforced the idea that the immune system, and in 
particular autoimmunity, plays a central role in MS and provides strong evidence for the 
involvement of particular immune pathways in the pathogenesis of the disease. 
 Inflammation in MS has been found to only affect the CNS, suggesting that T and B cells 
are selectively recruited by CNS-specific antigens. There is evidence that inflammation of the PNS 
leads to peripheral neuropathy and the development of spontaneous pain (29, 100), however this 
exceeds the scope of this thesis. Despite the discovery of several promising candidate antigens as 
causative of MS through both animal and human studies, none of the proposed candidates has ever 
been confirmed (101, 102). This aberrant development of T cells that recognize self-antigens leads 
to autoimmunity and evokes widespread myelin destruction. Originally, it was posited that myelin 
proteins generated as a result of oligodendrocyte destruction were driving the antigen-specific 
immune response (30). However, both healthy and MS patients have been reported to have similar 
numbers of myelin specific T cells, therefore, a yet known trigger must occur to initiate a loss of 
self-tolerance to myelin peptides. Nevertheless, the responses mediated by the circulating 
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autoreactive T cells have substantial qualitative differences, most notably that myelin-reactive T 
cells from MS patients have a robust memory or activated phenotype, whereas in healthy persons 
they have a predominantly naive phenotype (103, 104). This was evidenced in a clinical trial in 
which MS patients were treated with an altered peptide ligand of MBP, which in mice seemed to 
reduce the pathogenic T cell population and induce a tolerized T cell population, but in humans 
resulted in disease exacerbation as a result of an up to 2,000-fold expansion of circulating MBP-
specific CD4+ T cells (105). Growing evidence points to a diverse repertoire of specificities 
implicated in driving the disease process (30, 106-108) in addition to the observed myelin-driven 
response.  
 For the purposes of this thesis, I will broadly discuss the major T cell subtypes (e.g., CD4+ 
and CD8+) as they relate to disease pathogenesis and not delve deeper into the nuances and 
specifics of these and other immune cell types (e.g., B cells) as CD3+ T cells are the most 
numerous lymphocytes in the MS brain in all lesions and at all stages of the disease (74). For 
instance, in the majority of MS cases, there is considerable agreement that the disease process 
underlying the development of MS starts with increased migration of autoreactive CD3+ T 
lymphocytes across a weakened BBB (30) by adhering to the luminal surface of endothelial cells 
and migrating into the CNS (46, 109). What initiates the transition of these lymphocytes from 
physiological surveillance to a pathological cascade is thought to arise from regulatory defects that 
allows these cells to set up an immune response within the brain. This is evidenced by the lack of 
regulatory control of lymphocytes in people with MS to effectively carry out suppressive functions 
on effector cells, which can result in a breakdown of immunologic self-tolerance to antigens (110). 
For example, analysis of CD4+ T cells from MS patients were found to have significantly 
increased β-arrestin 1 expression (111). β-arrestin 1 is a key promoter of naïve and activated CD4+ 
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T cell survival. Therefore, it is thought that these β-arrestin 1 overexpressing cells do not 
effectively apoptose on stimulation, increasing the patient’s susceptibility to autoimmunity (111).  
 Once in the CNS, there is a significant immune response following local T cell reactivation 
to self-myelin and non-myelin antigens through the help of APCS, which recruits additional T 
cells and macrophages that establish the inflammatory lesions (112).  Antigens on the myelin 
sheaths or oligodendrocyte soma can be recognized by these cells and cause demyelination and 
oligodendrocyte destruction, which results in extensive axonal damage as previously mentioned 
in preceding sections (46, 112). Despite MS being thought of as a CD4+ T cell driven disease, 
CD8+ T cells have been shown to outnumber all other lymphocytes being widely distributed within 
the parenchyma and at the edge of CNS lesions (31, 113). For example, perivascular cuffs at the 
edge of active demyelinating lesions in progressive MS contain up to 50 times more CD8+ cells 
than CD4+ cells (69, 114), whereas the CD4+:CD8+ ratio in the CSF ranges from 3:1 to 6:1 and 
in the peripheral blood is 2:1 in MS patients (69, 115). A portion of the CD8 T cells isolated from 
the CNS of patients with MS exhibited evidence of oligoclonal expansion, indicating that these 
cells had been amplified via antigen-specific responses (116). In fact, the oligoclonally expanded 
CD8 T cells were shown to exist not only in the CNS, but also in the CSF and blood in a small 
number of tested patients, where, strikingly, some of the expanded CD8 T cells had persisted in 
the blood and CSF for several years (69, 116). Lastly, CD8+ T cells have been observed as 
outnumbering CD4+ T cells in MS lesions, evincing the importance of this T cell subtype as a 
major driver in disease pathogenesis in MS patients (117). CD4+ T cells, on the other hand, have 
been found to be far more concentrated in the perivascular and meningeal cuffs and to a lesser 
degree in the lesion environment (69, 89, 118, 119). Other cells can also contribute to the damage 
of oligodendrocytes and myelin, including microglia and macrophages through the production of 
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pro-inflammatory cytokines and generation of ROS (46, 112). However, the complexity of the 
immune-response and the subset of cells, factors, and mechanisms involved, while important, 
exceed the scope of my thesis work. What is apparent, though, is demyelination strongly correlates 
with disease progression and clinical disability in MS patients. Despite strong evidence for a 
critical role of the immune system in disease initiation and development, disease-modifying 
therapies do not stop the progression of the disease and the accumulation of permanent 
neurological deficits. Therefore, developing therapeutic strategies to dampen the immune response 
and lessen the accumulation of irreversible deficits is critical to slowing the course of the disease. 
 
VI. Role of Astrocytes in Multiple Sclerosis 
 Histological analysis of human brains has revealed that approximately 30% of all glial cells 
(i.e., microglia, oligodendrocytes, astrocytes) in the CNS are astrocytes, where individual 
astrocytes occupy unique territories demarcated by non-overlapping, star-shaped processes that 
extend from the cell soma (120, 121). Astrocytes are diverse cells, which is not unexpected given 
the range of functions attributed to these cells in the normal functioning of the CNS. As 
components of the neurovascular unit, distal end feet of astrocyte processes form the glia limitans, 
which contributes to the maintenance of BBB integrity and forms a secondary barrier that restricts 
peripheral immune cells from easily accessing the CNS parenchyma (Figure 1-3). White matter 
astrocytes are found to be functionally connected to adjacent astrocytes and to oligodendrocytes 
by gap junctions, forming ‘large syncytium-like glial networks that are composed of hundreds of 
cells’ (122, 123). Astrocytes are critically involved in the maintenance of neurons through 
buffering of extracellular neurotransmitters (124) and secretion of trophic factors (125), regulation 
of neuronal synaptic transmission (126, 127), and pruning of synapses (128). Moreover, astrocytes 
in the healthy CNS contribute to an anti-inflammatory environment through constitutive low-level 
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secretion of anti-inflammatory factors (129-131). Therefore, changes in astrocyte function as a 
result of trauma, disease, or inflammation can lead to drastic alterations in the normal functioning 
of the CNS. Growing evidence of astrocyte dysfunction in MS supports this claim and points to an 
underlying etiology for astrocytes during disease pathogenesis. 
 Immune responses in MS involve both the adaptive and innate arms of the immune system, 
which induces profound alterations in CNS cells during the progressive stages of the disease. 
Under normal, healthy conditions homeostatically active astrocytes carry-out the diverse functions 
that have been described above. However, following injury or inflammation (as in the case of MS), 
astrocyte reactivity is triggered by oxidative and chemical stressors, pro-inflammatory cytokines, 
and damaged-associated molecular patterns, released, in this context, as a result of myelin damage 
(132-134). This major phenotypic change in astrocytes is known as “astrogliosis” or “reactive 
gliosis,” which will be used interchangeably throughout this section (135).  
 Astrogliosis is characterized by a hypertrophied morphology and chronic changes to the 
gene expression profile, most noticeably the increased expression of GFAP. As a results, reactive 
astrocytes can increase the secretion of chemokines and cell adhesion molecules, which can 
amplify or activate a peripheral immune response (123). As a result, reactive astrocytes have 
recently been categorically defined as “A1” or “A2” according to their transcriptomic profiles, 
which is an analogy to the “M1” and “M2” phenotype categories given to macrophages (135, 136) 
(Figure 1-4). A1-type astrocytes, which complement component 3 is an identifying marker, are 
induced by inflammation, are abundant in MS and other neurodegenerative diseases, and have 
been found to secrete a yet to be identified neurotoxin that selectively kills neurons and 
oligodendrocytes (136, 137). Transcriptomic analysis of neuroinflammatory A1-type astrocytes 
revealed an up-regulation of genes that have previously been shown to be destructive, suggesting 
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that A1-types have harmful functions. In contrast, A2-type astrocytes have been found to be 
induced by ischemia and show up-regulation of neurotrophic factors and thrombospondins, which 
promote survival and growth and synapse repair, respectively (136). This suggests a “helpful” 
function of the A2-type astrocytes. However, as the concept of M1/M2 polarization is now 
considered an oversimplification of the continuum of phenotypes macrophages can fulfill and has 
been abandoned in a formal sense, it is important to consider a similar continuum existing for the 
heterogenous populations of astrocytes in both health and disease.  
 It has been proposed that there are common cellular and molecular features of reactive 
astrogliosis (135, 136, 138). This implies that the unique properties of these cells may be specific 
to the neuropathology under which they are studied (139, 140). Moreover, the development of 
distinctive astrocyte phenotypes may be dependent on the different phases of a pathological 
process. Broadly, reactive astrocytes initially increase the production and release of pro-
inflammatory cytokines and ROS in association with hypertrophy and proliferation. This is 
followed by a second “recovery” phase, wherein astrocytes promote anti-inflammatory and 
neuroregenerative functions through the release of neurotrophic factors (141). Thus, reactive 
astrocytes can mount powerful inflammatory responses that drive leukocyte recruitment to the 
CNS and aid in the resolution of inflammation through a change in response profiles to an A2-
type, as well as lead to formation of glial scars that isolate the inflamed area, restrict damage, and 
provide structural support (120).  
 In MS, astrocytes are increasingly recognized as cells that critically and actively contribute 
to the development of MS lesions (142, 143). This is in contrast to the previous notion that 
astrocytes were only believed to be reactive at a late, post-inflammatory stage by forming a glial 
scar (142, 144). In active MS lesions, astrogliosis is a common feature recognizable by 
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hypertrophic morphology and reduced process density (142). A hypertophic morphology in 
reactive astrocytes is indicative of substantial tissue injury, which is thought to be caused in MS 
lesions by oligodendrocyte loss and the resulting disruption of the astrocyte-oligodendrocyte 
network (122, 142). As well, reactive astrocytes themselves have been identified as sustaining 
substantial damage (145), which can lead to loss of the glia limitans around blood vessels further 
increasing the access of immune cells to the CNS (123, 142). Reactive astrocytes have been found 
to reside within the active margins of demyelinating lesions, where they can extend into adjacent, 
NAWM, which suggests astrogliosis as an early contributor to lesion development (142, 144). This 
has been supported by observations in the murine EAE model of MS that astrocytes in nascent 
lesions are activated prior to any significant infiltration of immune cells into the parenchyma takes 
place (146-148). Interestingly, hypertrophic astrocytes at the leading edge of actively 
demyelinating lesions have been found to contain myelin debris (144). This elegant study 
demonstrated that myelin-debris uptake by reactive astrocytes induces NF-κB signaling and 
secretion of cell-recruiting chemokines. This led to the authors hypothesizing that the uptake of 
damaged myelin by astrocytes might be an early trigger that leads to astrogliosis, resulting in an 
astrocyte-mediated influx of leukocytes during the very early stages of lesion development (144). 
However, this result must be viewed with caution. Observations of expression of MHC class II 
and the co-stimulatory molecules CD80 and CD86 by astrocytes within MS lesions supports 
myelin phagocytosis by astrocytes as a non-traditional means of antigen presentation of myelin 
antigens to T cells. Yet, it has been shown that human astrocytes in culture fail to induce, or 
actively inhibit, the proliferation of T cells (149), leaving it either unlikely that astrocytes are 
capable of competent antigen-presentation in MS lesions or that the mode of stimulating astrocytes 
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to present antigens in myelin lesions is not yet appropriately modeled in vitro  (123). This 
intriguing possibility is supported by studies from others and warrants future investigation. 
 While astrocytes are not considered capable APCs, they are known to modulate immune 
responses. Reactive astrocytes have been shown to produce chemokines as well as cell adhesion 
molecules that are commonly associated with macrophage/microglia and lymphocyte recruitment 
into the CNS parenchyma (123, 150). Mouse models have enabled the elucidation of functionally 
relevant roles for astrocytes in leukocyte recruitment. For instance, mice with a conditional, 
astrocyte-specific gene deletion of CCL2 when EAE-immunized and studied for clinical disease 
course were found to develop a less severe EAE disease course, lowered macrophage and T cell 
infiltration, and a reduction in astro- and microgliosis (151). Conversely, astrocyte-mediated 
recruitment of microglia to demyelinating lesions can also beneficial. This was demonstrated in a 
cuprizone-induced demyelination, which does not cause BBB disruption or involve peripheral 
immune cell infiltration (152). Astrocytes were genetically ablated in mice treated with cuprizone, 
which prevented the recruitment of microglia to sites of demyelination, leading to a delayed 
removal of myelin debris, impaired remyelination, and reduced proliferation of OPCs (153). 
Therefore, it seems that astrocytes are key in regulating the recruitment and removal of damaged 
myelin in MS, which is needed before remyelination can take place (153). 
 While reactive astrocytes are known to drive a subset of inflammatory and neurotoxic 
responses in MS lesions, they may concurrently dampen inflammation and promote 
neuroregeneration within lesions. One well studied neurotrophic factor produced and secreted by 
astrocytes and neurons in the healthy CNS that may have beneficial effects is brain-derived 
neurotrophic factor (BDNF) (154, 155). Deletion of BDNF in astrocytes during EAE resulted in a 
more severe clinical course, whereas enhanced BDNF production by astrocytes in the cuprizone 
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model enhanced remyelination (156, 157). This has been corroborated in humans as BDNF has 
primarily been found in immune cells and reactive astrocytes in MS lesions (158). Furthermore, 
the generation of the glial scar following acute inflammation and demyelination in the center of 
white matter lesions has a dual role.  
 Chronic activation of astrocytes is known to develop what is known as the glial scar. The 
purpose of the glial scar was originally thought to restrict the spread of inflammatory cells and 
limit damage to the surrounding, unaffected tissue by creating a barrier that prevents the spread of 
immune cells and toxic levels of extracellular ions, metabolites, and DAMPs (120, 142).  While in 
some cases this has been considered to restrict tissue regeneration, the glial scar also provides 
beneficial features that directly contribute to recovery from CNS insults. For example, glial scars 
have been found to support demyelinated axons and restore BBB integrity and function (120, 142). 
However, much remains to be understood about the ying and yang of glial scarring to provide 
functional and mechanistic insight into what pathways or factors can be targeted therapeutically to 
promote a more robust regenerative effect within MS lesions. 
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Figure 1-3: Astrocyte endfoot processes form the glia limitans as part of the neurovascular 
unit. (A) astrocyte foot processes associate with the basement membrane of the endothelial cell 
layer to form the glia limitans to prevent the free movement of cells and small molecules into the 
brain parenchyma. (B) Cross-sectional view a blood vessel within the CNS showcasing the 
structure of the BBB—astrocyte endfoot processes, endothelial cells, and tight junctions. 
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Figure 1-4: Categorization of reactive astrocyte phenotypes lies on a spectrum. (A) Astrocytes 
so far have been categorically defined to exist in two distinct reactive states. If this is the case, it 
is possible to conceive that they exist as a continuum, with a heterogenous mixed population of 
both inflammatory A1-type astrocytes and anti-inflammatory A2-type astrocytes. (B) In another 
model that involves alternative reactive-astrocyte polarization states, multiple reactive phenotypes 
exist, with ‘n’ number of possibilities. However, it is currently unknown which of these models 
best describes reactive-astrocytes, therefore use of single-cell genomic and proteomic analysis 
should aid in answering this question in the future. Figure is from Liddelow and Barres, 2017 
(136).  
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VII. Animal models of CNS Demyelination 
 Animal models have been vitally important to the study of human diseases. They have 
allowed researchers a living tool that can be manipulated to answer many of the unresolved 
questions regarding a multitude of human diseases, from elucidating critical mechanisms of the 
disease processes, to identifying major cell types involved, and in the development of disease 
modifying therapies. In MS specifically, there are three main animal models— experimental 
autoimmune encephalomyelitis (EAE), toxin-induced demyelination, and dietary cuprizone 
intoxication (discussed below)—used to study how demyelination in the CNS contributes to 
disease pathogenesis, remyelination potential, and modeling the progressive form of the disease, 
respectively. 
 EAE was first described in the 1930s when researchers at Rockefeller University 
discovered the model as way to study the episodes of paralysis that occasionally occurred 
following convalescence of certain viral infections like smallpox and in some circumstances to 
vaccinations like rabies (96, 159). Initially, the EAE model was viewed as a way to understand 
ADEM, not MS. However, over the past 75 years  numerous refinements and variations have been 
developed to better model many of the features common to MS: demyelination and axonal damage, 
relapsing-remitting episodes of paralysis, and autoreactive T lymphocytes to myelin antigens 
(160).  
 Currently, EAE is the most commonly used animal model to study MS and is best served 
as a way to model and study the inflammatory components of the disease. The inflammation, 
demyelination, and clinical phenotype associated with EAE varies based on the myelin peptide 
used. Common myelin peptides used in the induction of EAE include: peptide residues 35-55 of 
myelin oligodendrocyte glycoprotein (MOG35-55); proteolipid protein (PLP); and peptide residues 
 35 
1-37 of myelin basic protein (MBP). Once the myelin peptide is chosen, it is then emulsified in 
either complete or incomplete Freund’s Adjuvant (with or without mycobacterium tuberculosis, 
respectively) followed by an injection of pertussis toxin, which is thought to increase the 
permeability of the BBB and sensitize the immune system to the myelin peptide self antigens (161-
164). The clinical and pathological course of EAE is also highly dependent on the mouse strain 
and immunizing peptide used and careful consideration of the disease process under study must 
be taken into account (165). For example, EAE induction in C57BL/6J mice using the MOG35-55 
peptide results in a well-characterized and highly reproducible monophasic disease course 
consisting of an immune response comprised predominately of autoreactive CD4+ T lymphocytes, 
demyelination within the CNS, and an ascending paralysis clinical component (164). Despite 
replicating many of the common features of the MS disease process, the murine MOG35-55-EAE 
does not capture the relapsing-remitting phenotype. Therefore, to study the mechanism(s) 
underlying the relapsing-remitting phenotype, a variant of EAE was developed using SJL (Swiss 
Jim Lambert) mice immunized against the MBP or PLP peptide (166-168). The disease in this 
mouse is characterized by a relapsing-remitting course of paralysis, which can allow for the 
assessment of the efficacy of various immunoregulatory strategies in a progressive autoimmune 
disease setting (169). 
 The EAE model in spite of the tremendous insights it has provided as a model of MS is far 
from a perfect recapitulation of MS disease as it lacks some salient features of the human disease 
(170). One facet of the EAE animal model that has been under growing scrutiny is the 
predominance of  autoreactive CD4+ T cells in the absence of whereas CD8+ T cells, the latter of 
which are known to occur at higher frequency in the human disease and far outnumber the presence 
of CD4+ T cells within the CNS compartment, drive disease progression (117). Additionally, due 
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to the spontaneous development of demyelinated lesions in this model, studying the processes 
involved in remyelination is also challenging if not impossible. In spite of these caveats of the 
murine model of MS, EAE has proven useful in the development of drugs to treat the inflammatory 
component of MS even if its caveats foreshadow the need for better modeling of the human disease 
Currently, four of the sixteen approved MS DMTs were developed following promising results in 
this model, including: glatiramer acetate, mitoxantrone, fingolimod, and natalizumab (96, 171). 
Future treatments may require developing animal models that better replicate many of the critical 
aspects of the human disease are needed. In part, this aspect of animal modeling and the need to 
better model human disease, is a component of my thesis studies (see chapter 4). 
 In the following paragraphs, I will briefly cover additional animal models used in the study 
of MS. While these models were not used to generate any results in this thesis, and will not be 
covered in depth, they complement emerging concepts for remyelinating therapies and I highlight 
the uniqueness of these models for addressing questions that cannot be answered using EAE.  
 Toxin-induced models of demyelination involves the microinjection of chemical to induce 
focal demyelinating lesions in the CNS. Lysophospatidylcholine (lysolecithin) or other toxins 
when injected into the spinal cord white matter of mice induce demyelination that also 
spontaneously remyelinates. For this reason, chemical lesions of white matter represent models 
well suited for study of the molecular and cellular components underlying remyelination following 
injury ( 164, 172). Application of the toxin results in the formation of a focal lesion that has a 
reproducible and distinct remyelination timeline that is used to study the processes of active 
remyelination (172), which is almost impossible to undertake in EAE due to the aforementioned 
spontaneous lesion development. However, the lack of an immune component in this model of 
demyelination is a major weakness that limits the scope of the of questions the model can answer. 
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 Another widely used model of CNS demyelination is the dietary neurotoxicant called 
cuprizone. This model is used extensively to study PPMS as both share a common feature of 
demyelination and remyelination without immune cell involvement (173).  Cuprizone is a copper 
chelator that was originally used as a model to induce a spongiform encephalopathy (prion-like 
pathology) (174). However, for modeling PPMS, cuprizone is administered orally through mixing 
with regular rodent chow that reproducibly evokes a robust and predictable CNS demyelination, 
which is most noticeable in the corpus callosum (173). The site of injury is both reliable and 
consistent and provides a useful tool in studying the events underlying remyelination in the white 
matter. However, the exact mechanism of demyelination is not fully understood, but it is known 
that the apoptosis of OLs occurs (164). 
 
VIII. Current Disease Modifying Therapies and Future Strategies 
 The longstanding first line treatment or MS, employed since the early 1950s, has been 
corticosteroids. These are still seen as the “war horse” therapy in the treatment of autoimmune 
disorders and have represented the standard of care for decades (175, 176). Currently, however, 
steroids are only prescribed for acute relapses, which work to reduce the levels of circulating 
cytokines by inhibiting production and dampening the activation of the peripheral immune system 
(177). This helps to reduce the severity of clinical symptoms associated with relapses and increase 
the speed of recovery, but no evidence exists that corticosteroids prevent new relapses from 
occurring or influences the progression of the disease (178). 
 Remarkable advances have been made in the treatment of MS over the last 60 years, with 
the predominance of current treatments for MS focusing on modifying the disease course by 
diminishing the autoreactive T cell response. There are 15 DMTs approved by the FDA for MS as 
of 2017: five preparations of interferon beta; 2 preparations of glatiramer acetate; the monoclonal 
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antibodies natalizumab, alemtuzumab, daclizumab, and ocrelizumab; the chemotherapeutic agent 
mitoxantrone; and the small-molecule oral agents fingolimod, dimethylfumarate, and 
terifluonomide (31, 69). All of the FDA approved drugs have been designed to target some 
component of the immune system and virtually every drug impacts the inflammatory relapsing 
stage of the disease, leaving the treatment for the progressive forms of MS as an unmet need (69). 
It is beyond the scope of this thesis to discuss the relative benefits, risks, modes of action, and 
routes of administration of these various medications. It must be noted, though, that all the current 
FDA drugs to treat MS have been approved for treating the relapsing-remitting form of the disease 
and reduce, to various extents, the likelihood of the development of new white-matter lesions, 
clinical relapses, and accumulation of neurologic disability (31). Instead, emerging therapeutic 
strategies will be covered and where the trajectory of future therapies is focused.  
 An exciting and newly emerging therapeutic strategy in the treatment of MS is stem-cell 
transplantation. Small-scale studies have been conducted and shown that ablation of the immune 
system through chemotherapy and immune-depleting antibodies followed by autologous 
hematopoietic stem-cell transplantation may be a highly durable and effective—and increasingly 
safe—therapy (31). Longitudinal studies on a small cohort of RRMS patients from a single-group 
phase-2 trial revealed an almost full halt to all detectable CNS inflammatory activity and relapse 
frequency in the absence of any ongoing DMTs (31, 179). Additionally, 35% of patients showed 
sustained improvement in their EDSS score, making this an attractive future therapy for the 
treatment of MS (179). In the search for more specific immune-cell targeted therapies, early-stage 
efforts to interfere with specific T cell populations that are thought to drive MS, stemming from 
data collected from murine EAE experiments, indicates that certain key subsets of helper T cells 
are important and are actively being investigated (180, 181). Such approaches may involve specific 
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inhibition, clonal deletion, or induction of immunotolerance (31). Despite strong evidence of 
involvement of the innate immune system in MS, no large-scale trials have been conducted that 
specifically targeted this system for treatment in MS (31). This is likely due to both the protective 
and deleterious roles inherent within the system, hampering efforts to appropriately target this 
system for therapeutic intervention (31, 182). Nonetheless, due to the pervasive presence of innate 
immune cells in and around MS lesions underscores the need for further research. 
 New strategies to treat MS may require moving beyond the immune system for the 
development of targeted therapies. Specifically, an increasing number of studies has focused upon 
tissue repair and protection (183). Looking at the repair side, small studies have been conducted 
with therapies that promote endogenous remyelination through specific pathways (e.g. anti-
LINGO-1), however preliminary results have been mixed (184). Further, based on pre-clinical data 
using in vitro screens and testing in EAE models, several previously approved FDA drugs (e.g. 
clemastine) are being tested for remyelination or myelin protection (31, 185). The transplantation 
of neural or OPCs into the brain has also proven to be an effective strategy to promote endogenous 
repair in animal models (186), however no well-designed clinical trials involving MS patients has 
been undertaken despite the likelihood that promoting endogenous remyelination will prove to be 
a more viable and feasible strategy in treating MS (187). Lastly, strategies to target axonal 
protection are actively being examined (188). Encouraging results from initial clinical trials testing 
a wide variety of drugs has been published or reported, which have lead to several medium-to-
large studies that are currently under way (188). The idea(s) driving this area of active investigation 
is that slowing the rate of cerebral or spinal cord atrophy is a feasible goal based on initial findings 
to this point, and that a proof-of-concept trial could be undertaken in several hundred people over 
a period of a few years (189). 
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 Currently, there are is only one FDA-approved drugs for therapeutic intervention PPMS 
patients. This recently approved agent target B cells and has only been found to attenuate disease 
marginally in a subset of patients (190). The current standard of care therapies used by physicians 
to treat MS are called DMTs that primarily target immune cells as a strategy to reduce 
inflammation and the frequency and severity of relapses, which improves the quality of life of 
those with RRMS; whereas SPMS develop a lack of responsiveness to current therapies and PPMS 
patients have so-far been refractory to all current DMTs. Thus, DMTs are not an effective strategy 
for treating progressive forms of MS (50, 191). Therefore, rigorous investigation into the 
underlying cause of disease progression in the etiology of progressive disease in MS (i.e., loss of 
regenerative potential) provides potential new avenues for the development of novel therapeutics 
to treat patients with the potential to treat the underlying cause in all MS patients. 
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Chapter 2. Extracellular Vesicles 
I. Brief History of Extracellular Vesicles  
 The study of extracellular vesicles (EVs) traces its roots back to the late 1940s. The first 
observations of EVs were made following preliminary studies addressing the “biological 
significance of the thromboplastic protein of blood” (192). In this seminal investigation, Chargaff 
and colleagues examined the clotting times of plasma and explored how separation of plasma by 
centrifugation at different speeds when they observed that prolonged, high-speed centrifugation 
extended the clotting time of the supernatant. They then found that application of the pellet 
containing “the clotting factor of which plasma is derived” to plasma could induce a shorter 
clotting time. This led the authors to speculate that cell-free plasma contains a sub-cellular factor 
that could promote blood coagulation (192). However, it was not for another 20 years, in 1967, 
that that subcellular factor was identified through electron microscopy and small vesicles, which 
were at that time referred to as “platelet dust”, were identified (193). From the 1970s into the 
1980s, more independent observations of extracellular vesicles were reported as being released 
from the plasma membrane of rectal adenoma microvillus cells (194), as virus-like particles in 
human cell cultures and bovine serum (195, 196), and from seminal plasma (197). It was a 
subsequent detailed, ultrastructural study performed in 1983 that examined EVs from 
differentiating immature red blood cells and identified a putative mechanism for vesicle release. 
Specifically, they observed that vesicle-filled endosomes, termed MVBs, could fuse with the cell 
membrane and releasing their vesicles into the extracellular space (198-200). More than a decade 
after this finding, Epstein-Barr virus-transformed B lymphocytes were found to secrete antigen-
presenting extracellular vesicles that were themselves capable of inducing T cell responses (201). 
Building off these salient findings and supplementing with the discovery of EVs containing RNA 
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and proteins, there has a resurgence in interest in determining whether EVs are significant 
mediators of cell-to-cell communication and their contributions in pathological settings (202, 203).  
 Due to the increasing data on EV structure, function, and content, a coalition of EV 
researchers formed the International society of Extracellular Vesicles (ISEV) in 2011 with the 
expressed aim to unify the nomenclature and methodologies of EV research. Hence, the journey 
of EVs from “platelet dust” to significant mediators of cell-to-cell communication has led to the 
investigations of EVs as potential biomarkers in an array of diseases, as initiators and facilitators 
of disease pathogenesis, and as therapeutic tools. My thesis work tackles two important areas of 
EV research: (1) my initial work aimed to identify a cell-specific marker of EVs, which is currently 
lacking in the field, for potential use as a diagnostic monitoring tool of disease activity in MS, and 
(2) elucidate the immunomodulatory function(s) of plasma EVs during disease exacerbation, an 
area of active research. There is still much to be learned, but the future is bright for these small 
vesicles. 
 
II. Extracellular Vesicle Subtypes 
 The traditional view of how extracellular vesicles contribute to cellular communication is 
that cells secrete a limited repertoire of proteins as cargo in EVs through the secretory pathway 
[e.g., endoplasmic reticulum to Golgi to plasma membrane]. Cells then can release and/or take up 
small molecules through transport channels and additional post-Golgi secretory vesicles, which 
has collectively been termed the secretome (204, 205). However, it has become increasingly clear 
that this is an outdated view of cellular communication. Newer insights into mechanisms of cell-
to-cell communication, vis-a-vis secreted vesicles, is bringing to light a more complex and diverse 
process than ever previously thought. There is now compelling evidence that nearly all cell types 
are capable of releasing EVs. EVs come in a diverse range of sizes, collectively referred to as 
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extracellular vesicles, but with subclasses within the category of EVs having been given specific 
labels, such as exosomes (see below). It is also clear that use of EVs inter-cellular communication 
is not an adaptation limited to higher organisms as this process of EV-mediated communication is 
evolutionarily conserved from bacteria to plants to humans (206-208). That EVs are no longer 
thought of as simply ‘cellular dust,’ EVs are now seen as key players in intercellular and even 
interorganismal communication. As a result of these findings, one of the main interests in the field 
is to elucidate the capabilities of EVs to exchange biological materials between cells—RNA, 
miRNA, proteins, and lipids—and further understand their role as signaling in the maintenance of 
normal cell homeostatic processes and also in the context of disease or pathological states (209-
211).  
 Currently, the field of EV biology has settled on using the generic term ‘extracellular 
vesicles’ to refer to all secreted membraneous vesicles (212). A large amount of work has been 
dedicated to understanding the protein and lipid components of EVs, as well as their physiological 
relevance, and this is an active and rapidly expanding field of study (204). We now know that the 
generic term ‘EV’ encompasses a highly heterogenous collection of membrane-bound carriers with 
complex cargoes which are present in a myriad of biological fluids, including: saliva, urine, nasal 
and bronchial lavage fluid, plasma, serum, and seminal fluid (209, 213-216). Whereas in years 
past there have been a myriad of labels for different EVs, insights into the biogenesis of EVs using 
electron microscopy and biochemical markers has resulted in broadly dividing EVs into two main 
categories: exosomes and microvesicles (217-219). 
 Exosomes are small, nanosized vesicles roughly 30-150 nm in diameter (220) that are 
thought to be released by all cells and are present in many and perhaps all biological fluids (213, 
214, 221, 222). The nomenclature of ‘exosome’ was initially used to describe vesicles of an 
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unknown origin released from a variety of cultured cells and carrying 5’-nucleotidase activity 
(223). This term was then subsequently adopted to define membrane vesicles (30-150 nm in 
diameter) released by reticulocytes during differentiation (200) but has since been extended to 
identify all vesicles released from cells that fit within this size range. Exosomes have been 
morphologically characterized as having a ‘cup shaped’ appearance when visualized by 
transmission electron microscopy (TEM) (224). However, whether this is a unique feature of 
exosomes or simply an artifact due to extensive sample preparation for TEM is not currently 
known (225). With regard to their biochemical composition, exosomes have a phospholipid bi-
layer membrane containing relatively high levels of cholesterol, sphingomyelin, ceramide, and 
detergent-resistant membrane domains (i.e., lipid rafts) (226-229). Of particular interest to 
understanding diseases and the contributions of exosomes to disease processes, exosomes are 
thought to retain cell-type specific markers of the cell of origin. This feature offers the potential to 
allow for identification of the cellular source(s) of exosomes in complex biological fluids. More 
broadly, exosomes can been identified by presence of the tetraspanin protein CD63, specific lipid 
raft-associated proteins, including flotillin-1 as well as internal, endosomal markers such as Alix 
and TSG101 (230).  
 “Microvesicles” (MVs) is a term used to specify extracellular vesicles that are released 
from the plasma membrane during episodes of cellular stress. This subclass of EVs were initially 
thought of as ‘platelet dust’, having first been described as subcellular components that originated 
and were released from platelets in plasma and serum (193). Although MVs have mainly been 
studied for their role in blood coagulation, more recently, these EVs have been reported to play a 
role in direct cell-cell communication among various cell types. MVs have been identified in many 
of the same biological fluids where exosomes have been found. MVs are defined over a wider 
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range of sizes than exosomes—50 to 500 nm in diameter, with some being up to 1 µm—with 
phosphatidylserine (PS) often mentioned as a typical marker (228, 231). However, the use of PS 
as a marker of MVs is questionable at best given the significant number of MVs that do not express 
PS (232, 233).    
 Despite efforts to categorize extracellular vesicle subtypes based on specific sizes, 
morphology, and/or molecular markers, the extensive overlap in size classes, the similar ities in 
vesicular morphologies, as well as the variable compositions have ultimately limited our ability to 
devise a more precise nomenclature for EVs (234, 235). In fact, due to increasing evidence pointing 
to a significant overlap in the characteristics previously thought to uniquely identify exosomes and 
MVs suggests that a future iteration of EV nomenclature may offer a spectrum of vesicle types 
with overlapping and unique properties present in all biological fluids (224). However, great 
strides have been made in developing isolation and characterization methods that will allow for a 
more thorough description of the respective functions of the different types of EVs, which will 
hopefully lead to the establishment of a suitable classification and terminology system in the near 
future (205). 
 
III. Extracellular Vesicle Biogenesis and Release 
 There are multiple mechanisms which drive the biogenesis of EVs. Each specific 
mechanism represents a significant determinant of the type of EV formed. One essential element 
of EV generation is that lipid curvature must be induced to form either an inward-budding vesicle 
within the endocytic system (i.e. exosomes) or an outward-budding vesicle at the plasma 
membrane (i.e. microvesicles) (204) (Figure 2-1A). A diverse array of mechanisms has been 
described for exosome biogenesis, however the best characterized mechanism involves the 
recruitment of the endosomal sorting complex required for transport (ESCRT) machinery to 
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ubiquitinated proteins in the early endosome (Figure 2-1B). The ESCRT machinery is comprised 
of four protein complexes—0, I, II, III—and critical accessory proteins (Alix, VPS4, and VTA-1) 
that act in concert to facilitate the formation and packaging of intraluminal vesicles (ILVs) (236). 
It should be noted that the ESCR-III complex is essential for the proper biogenesis of exosomes 
as it forms spirals that induce inward budding and fission of vesicles to form MVBs (237-239). A 
recently described alternative pathway of exosome formation involves the synthesis of ceramide 
as a mechanism to induce vesicle curvature and budding, which explains the observations of 
preferential loading of certain ceramide-dependent cargoes into ILVs of the MVB (240, 241). A 
third mechanism of exosome biogenesis has also been proposed which involves the tetraspanin-
mediated organization of specific proteins, such as the amyloidogenic protein premelanosome 
protein (PMEL) (242, 243). The observation and identification of multiple mechanisms of 
exosome biogenesis has only served to highlight the complexity of this biological process. 
Therefore, in the following paragraphs I want to broadly cover what is both known and unknown 
regarding exosome generation in order to put into context how much is left to discover about this 
process.  
 Initial studies into the ESCRT machinery driving exosome biogenesis identified an 
essential set of protein complexes that were thought to progressively execute stages of ILV 
formation. More recent data, however, suggest that not all of these components of the pathway are 
essential to EV biogenesis, with some complexes involved in the early stages of the biogenesis 
being more critical than later ones (204, 209, 244). The paradoxical nature of this is revealed when 
select ESCRT-0 and -I proteins are knocked-down and found to result in decreased exosome 
release. In contrast, knockdown of ESCRT components involved in the later stages of EV 
biogenesis had no effect or in fact were found to increase exosome release from cells (209, 244). 
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Further investigation applying simultaneous knockdown of multiple ESCRTs determined that 
ILVs are continuously formed however it should be noted that with knockdown fewer ILVs were 
formed, that these ILVs had an abnormal size, and these ILVs did not contain epidermal growth 
factor receptor (EGFR), a classic ubiquitinated protein sorted by ESCRTs to ILVs (245). Despite 
a growing awareness of the diverse and complex machineries involved in exosome biogenesis, it 
is not known whether these proposed pathways are distinct or interdependent (246). For example, 
the currently proposed ceramide mechanism only accounts for the membrane curvature function 
but does not explain cargo sorting (204). Additionally, it could be just as likely that cargo-sorting 
mediated by the ESCRT machinery could work in tandem with ceramide-induced lipid curvature 
to form and load exosomes. It is also possible that compensatory and redundant mechanisms may 
exist to allow for a low-level of constitutive ILV formation, even in the absence of specific 
complexes (204). This would also support an argument for a different process that could account 
for stress- or injury-induced changes in exosome production or content and release. Growing 
evidence of the diverse mechanisms at play in ILV formation highlights the ever-growing 
complexity of this process and further state-of-the-art techniques are needed to resolve these 
issues.  
 Despite abundant research into the mechanisms involved in exosome biogenesis, the 
mechanisms of microvesicle biogenesis (i.e. direct budding from the plasma membrane) are even 
less well known (204). Interestingly, one identified mechanism of MV generation involves the 
recruitment of the same ESCRT machinery involved in the formation of ILVs in the MVB, and in 
viral budding (Figure 2-1C). Recruitment of the ESCRT-III components involved in promoting 
the negative curvature needed to form and pinch off exosomes also performs the same function for 
generating MVs from the plasma membrane (236-239). This was observed in a system wherein 
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the adaptor protein arrestin domain-containing protein 1 (ARRDC1) was capable of recruiting the 
ESCRT proteins TSG101 (ESCRT-I) and VPS4 (accessory protein) to the plasma membrane 
(247). It should also be noted that vesicle budding can result from disruption or injury to the plasma 
membrane, which acts as a mechanism to repair the damaged membrane (248, 249).  
 Ceramide has also been found to be involved in MV generation. Alterations in the content 
of ceramide on the outer leaflet as a result of acid sphingomyelinase activation can induce 
membrane curvature and trigger MV release (250-252). There do not seem to be localized areas 
dedicated to MV release, as the shedding of vesicles has been shown to occur at multiple areas 
across the plasma membrane, including microvillar protrusions of intestinal epithelial cells (253) 
and from cilia (254). 
 The release of EVs by cells is dependent on the diverse cellular mechanisms involved in 
their mode of biogenesis (209). The budding and release of MVs occurs when membranous 
protrusions pinch off from the cell surface. Exosomes, on the other hand, derive from the endocytic 
system and are released when MVBs fuse with the plasma membrane. However, MVBs can 
undergo an alternate fate by fusing with lysosomes leading to the degradation and recycling of 
their protein, nucleotide, and lipid contents. Since exosomes are known to contain growth factors 
and other signaling molecules, the fusion of MVBs with lysosomes could be an internal control 
mechanism to prevent autocrine signaling from occurring. Similarly, fusion of MVBs with the 
plasma membrane leading to the direct release of exosomes could promote both autocrine and 
paracrine signaling (209, 244). Based on current evidence, the intracellular fate of MVBs to 
degrade or release could be influenced at numerous steps. These steps include the intracellular 
transport of MVBs along microtubules to the plasma membrane, creation of docking sites at the 
plasma membrane, or recruitment of soluble NSF attachment protein receptor (SNARE) proteins 
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that mediate fusion with either lysosomes or the plasma membrane. Additionally, the targeting of 
MVBs to lysosomes has been shown to occur as a result of autophagosomes-MVB fusion. 
Numerous molecular regulators have been implicated in exosome release including multiple 
molecules thought to be involved in MVB docking (e.g., GTPases Rab27a, Rab27b, Rab35, and 
RalA (255-257), the cortical actin regulator cortactin (258), as well as the fusion regulator 
synaptotagmin-7 (259), highlighting the diverse cellular components involved not only in the 
biogenesis but also release of EVs (Figure 2-1C). Understanding the factors and components 
intrinsically necessary for EV release will not only help to elucidate fundamental mechanisms of 
intercellular communication in development and homeostasis, but would be expected to provide 
important insights into cellular mechanisms of disease. 
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Figure 2-1: Molecular Machineries involved in EV biogenesis and release. (A) Biogenesis and 
release of microvesicles and exosomes from the cell. (B) Molecular machineries known to be 
involved in the biogenesis of exosomes. (C) Molecular machineries and proteins known to be 
involved in the release of microvesicles and exosomes from the cell. Figure adapted from Colombo 
et al, 2014 (209).  
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IV. Extracellular Vesicles and Neurodegenerative Diseases 
 Intercellular communication in neurodegenerative diseases is an active and growing area 
of research with potential for both biomarker and therapeutic development. The complex 
molecular events disrupted within a cell in a neurodegenerative disease cannot be overlooked for 
the potential impact on EV biology. Increasing numbers of studies point to secreted factors 
released from these cells having effects on neighboring or even distant cells that further support 
potential roles for EVs in neurological and neurodegenerative diseases. Therefore, in this section 
I will focus on our current understanding on the neurobiology of EVs as contributors and possible 
drivers of neurodegenerative disease pathogenesis.  
 A vast majority of cellular communication happens through the extracellular space and is 
viewed as an ideal ‘compartment’ for therapeutic intervention—to modify the disease—or to probe 
and sample for diagnostic assessment of disease progression (260). Over the last decade numerous 
mechanisms of cell-to-cell communication in neurodegenerative disease have been studied with 
exosomes and EVs consistently emerging as common players. Many of the mechanisms under 
study, including the clearance and disposal of toxic byproducts and molecules and the cell-to-cell 
transmission of inflammatory factors and aggregated or misfolded proteins involve some facet of 
EV function (260, 261). Despite most of these findings having been achieved in vitro, the 
advancements in the field have led to a greater understanding of the role of EVs in various 
neurodegenerative disease processes.  
 Many of the most common and well-studied neurodegenerative diseases are now known to 
have an EV component to them. Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic 
lateral sclerosis (ALS), Huntington’s disease, multiple sclerosis (MS), and the family of prion 
diseases all now have EV-mediated processes associated with them. I will broadly cover some of 
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the functions of EVs in each of these diseases with a central focus on what we know about EVs in 
MS. Additionally, to provide clarity in the descriptions and due to the disparate and, as of yet, 
unresolved categorical labeling of exosomes and microvesicles in the literature, I will refer to both 
classes as ‘extracellular vesicles’ rather than switch between exosome and microvesicle.  
 Many neurodegenerative diseases are now considered proteinopathies: diseases in which 
the release and deposition of toxic proteins contribute to pathogenesis. As a corollary of this, it is 
not surprising that EVs are now also being implicated as mechanisms of protein transport in these 
diseases. For example, in prion disease, evidence for an EV-mediated propagation of prion proteins 
has been identified wherein abnormal PrP are associated with EVs released from (PrP) expressing 
cells in vitro (262). Validation of this cellular mechanism comes from the in vivo identification of 
abnormal PrP associated with EVs from the CSF of sheep (222). Together, these findings support 
the established prion hypothesis which posits that an unknown trigger results in the aberrant 
protein confirmation of native PrP. This leads to transformed cellular conformation, PcP, to 
misfolded PrP proteins which then ‘transmit’ their misfolded state to additional ‘naive’ proteins. 
This cascade of protein misfolding results in aggregates of oligomers that form fibrils that trigger 
a chain-reaction of refolding and aggregation that can spread to other cells and results in tissue 
destruction and neurodegeneration (263, 264). Moreover, the prion hypothesis now places EVs as 
a vital element in that process of dissemination PrP.  
 Similarly, in the proteopathies of Alzheimer’s and Parkinson’s diseases, a role for EVs in 
the progressive accumulation of misfolded proteins has also been identified. In AD, β-amyloid 
(265-268), tau (269-272), and in PD, α-synuclein (273-275), are known to accumulate in neural 
tissue and then spread with pathology often spanning neuroanatomically connected regions (260, 
264, 276). EV-associated hyperphosphorylated misfolded tau has been identified in the CSF of 
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AD patients (277). This supports in vitro studies which have reported EV-associated tau capable 
of being transmitted trans-synaptically via extracellular release. This EV-mediated transfer of tau 
highlights a potential novel mechanism for the progression of neurodegeneration via EV 
distribution of mutant tau within the brain of AD patients (260, 270, 271). Although a similar 
process has been suggested for PD, where α-synuclein has been identified in association with EVs 
(278, 279), the role of EVs in the spread of mutant α-synuclein is still a matter of considerable 
debate. Nevertheless, the key observation that EVs can accelerate aggregation of α-synuclein (274) 
points to one possible mechanism linking EVs to PD as well.  
 EVs have also been implicated in the pathogenesis of ALS and HD. In ALS, misfolding of 
the Cu/Zn SOD1 into aberrant conformations has been pinpointed as a critical and central event 
that drives the familiar and sporadic forms of the disease. The involvement of EVs in this process 
was discovered utilizing in vitro neuron and astrocyte cell-based models of the disease. Neurons 
expressing the mutant human form of SOD1 were shown to release the mutant protein in 
association with EVs into the extracellular space (280) resulting in the transmittance of this 
pathogenic trait to other neurons whereby it can propagate further misfolding and spreading of 
SOD1 (281). Astrocytes expressing a mutant version of the SOD1 protein have also been shown 
to release mutant SOD-1-in EVs and that SOD1 mutant astrocytes are known to be selectively 
toxic to motor neurons, the transfer of the mutant SOD-1 from astrocyte-derived EVs to then be 
detected in wildtype motor neurons again points to a pathogenic role of EV-mediated transfer of 
toxic proteins between cells (282). Any pathogenic role of EVs in HD is currently limited, 
however, evidence for cell-to-cell propagation of mutant Huntingtin (mtHtt), much like what has 
been reported to occur in PD, is supported by data from in vitro models of the disease. (283). 
Additionally, injection of human mtHtt-loaded EVs into the CNS of newborn, wild-type mice has 
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been shown to be sufficient to evoke Huntington disease-like symptoms and pathology in these 
wildtype recipient animals (283).  
 The contribution of EVs to MS pathology differs significantly when compared to the role 
of EVs in neurodegenerative diseases with respect to the wide body of literature on the role of EVs 
in primary proteopathies. Whereas growing evidence supports a role for EVs in the transfer of 
toxic proteins to target cells in ALS, PD, and HD that drive pathology, EVs in MS are thought to 
have a role in modulating the immune responses that drive disease progression. Specifically, given 
the central role of the immune system in MS, a role for EVs in regulating the activation of T cells 
and also facilitating the transendothelial migration of leukocytes across the BBB into the CNS has 
been reported (284).  
 In 1989, Scolding et al. were the first to demonstrate that recovery of oligodendrocytes 
from an injury involved the release of membrane-attack complexes enriched with complement 
proteins and galactocerebroside vesicles. These complexes emanated from the surface of viable 
cells and formed vesicles that could be isolated from the CSF of patients with suspected MS 
(compared to normal controls and patients with structural CNS damage) (285). These findings 
from Scolding’s work now support a prevailing hypothesis that repeated complement-dependent 
injury of oligodendrocytes, and their myelin membranes, contributes to the immunopathogenesis 
of MS. These seminal findings also provide a new perspective on how EVs released from 
oligodendrocytes during complement-mediated injury can protect these fragile cells from more 
extensive damage or dysfunction (285).  
 While in many instance, the cellular source of EVs are not well defined, it has been shown 
through in vitro studies that brain endothelial cells are capable of releasing EVs that can activate 
CD4+ and CD8+ T lymphocytes through the targeted expression of β2-microglobulin, MHC II, 
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CD40, and ICOSL (i.e. inducible costimulator-ligand) (286). Given the critical effector functions 
of CD4+ and CD8+ associated with the pathology of MS, these data point to a potential pool of 
circulating EVs derived from endothelial cells with immunomodulatory potential that can drive T 
cell activation in MS. This notion is supported by two findings: (1) that brain microvascular 
endothelial cells (BMEC) treated with plasma from MS patients results in increased release of EVs 
compared to treatment with normal plasma, and (2) elevated endothelial EVs are found in the 
plasma of MS patients (287, 288). Additionally, in conjunction with endothelial-derived EVs, 
platelet-derived EVs collected from MS patients have been found to increase the permeability of 
endothelial layers using in vitro models. These complementary findings suggest that EVs released 
from cells in vivo can work to disrupt the BBB and promote disease in a manner other than directly 
on T cells. Increased BBB permeability is a widely observed feature of MS pathology (289-291). 
Furthermore, there is also evidence that plasma EVs are capable of interacting and forming 
complexes with monocytes that can then induce their activation. Collectively, the findings of these 
studies point to EVs in potentially important roles mediating the transendothelial migration and 
activation of inflammatory cells in MS (292).  
 EVs derived from several cell types known to be involved in MS have also been implicated 
in disease progression and pathogenesis. In a relapsing-remitting EAE animal model, analysis of 
the CSF reported a significant increase in the concentration of myeloid-derived EVs. This was also 
closely associated with the clinical disease course and were found to propagate inflammatory 
signals; supporting a pathogenic role for these EVs in the disease (293). These findings in an 
animal model of MS parallel observations of increased myeloid-derived EVs in the CSF of 
relapsing-remitting patients compared to healthy control subjects (293). Interestingly, mice 
deficient for acid sphingomyelinase (aSMase), which controls the budding of EVs, have been 
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reported to be resistant to induction of EAE. However, these findings must be viewed in their 
appropriate context since aSMase mice are known to have defects in other processes relevant to 
developing EAE and so this finding, while potentially interesting, does not explicitly implicate 
EVs in the altered phenotype of these mice (293). Nevertheless, accumulating evidence suggests 
manifold roles for EVs in the inflammatory processes during MS pathology. Future studies will be 
necessary to decipher whether and how EVs participate in the interplay between inflammation and 
tissue degeneration in demyelinating diseases like MS. 
 
V. Extracellular Vesicles as Biomarkers in Neurodegenerative Diseases 
 The identification of neurodegenerative disease related proteins in EVs has led to growing 
interest in their use as putative biomarkers to monitor disease progression and as a minimally 
invasive means to monitor therapeutic effects of treatments. EVs can be readily isolated using non-
invasive techniques from multiple biofluids, including: urine, blood, and CSF; facilitating their 
use as clinical biomarkers (294-296). In moving towards the adoption of EVs as clinical 
biomarkers, the ability to objectively assess the diagnostic potential of EVs must be rooted in 
sound and reproducible standards for their use in identifying and monitoring the course of a given 
disease. However, despite the accessibility of these biofluids, current findings have been less than 
clear. For example, studies investigating quantitative differences in neurodegenerative disease 
related proteins in total CSF or associated with EVs purified from CSF have led to contradictory 
results in both AD and PD (297-299). In AD, an attempt at quantifying the disease-related protein 
hyperphosphorylated-tau in association with EVs found a significant increase in patients with mild 
forms of AD compared to controls (277). Despite this promising finding suggesting the 
measurement of tau phosphorylation in EVs could be employed as a clinical biomarker of the 
disease, moderate or severe forms of the disease do not show similar phosphorylation levels, 
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limiting the use of this approach (260). It has been suggested that one possible explanation of these 
disparate results is that the elevated levels of phosphorylated tau in EVs could be specific for the 
stage of the disease rather than the entire pathological process (260). With regard to PD, similarly 
contradictory results have also been reported in the literature. As an example, a recent report 
showed an increase in α-syn in EVs from PD patients while a different study from another group 
observed no variations in EV α-syn content (300, 301). Again, this discrepancy has been attributed 
to technical differences between lab, inherent difficulties in EV isolation, as well as the natural 
heterogeneity of these human patient populations (260).  
 EVs are known to be abundant with proteins and peptides. Therefore, recent initiatives 
have encouraged use of large-scale methodologies to analyze the proteinaceous EV content (e.g. 
LC-MS/MS and SILAC). For example, analysis of circulating EVs from healthy and PD patients 
using mass-spectrometry identified the enrichment of syntenin 1, a regulator of exosome 
biogenesis, in EVs from PD patients (301). Similarly, in EVs purified from control and prion-
infected cells, miRNA analysis revealed a distinct set of nine miRNAs enriched in EVs from prion-
infected cells, identifying a potential molecular signature that can be used to monitor the 
pathological process (302). However, caution must be used in evaluating the relevance of these 
“molecular signatures” as identifiers of the disease process. Instead, it may be more appropriate to 
establish a patient signature of changes in disease-related proteins in EVs. This would allow for 
the development of more precise diagnostic tools that can be applied to a specific patient’s disease 
course, rather than treating changes in disease-related proteins as applicable to all patients, which 
could lead to more directed therapeutic strategies to combat disease progression. 
 The widespread reporting of EV “counts” coupled with clinical evaluation of MS status 
together as biomarker of disease activity and progression was first suggested in 2001 by Minagar 
 59 
et al. The results from their study revealed that concentrations of CD51+ endothelial-derived EVs 
(EEVs) were higher during relapses than in remission, while a separate population of CD31+ EEVs 
were only higher during relapse when compared to healthy controls (287). Given these findings, 
they proposed that CD51+ EEVs were associated with chronic inflammation due to erosion of the 
endothelium of the BBB coupled with subendothelial matrix exposure, whereas CD31+ EEVs 
reflected acute endothelial damage. Additionally, the authors also described a concordance 
between CD31+ EEV counts and gadolinium enhancing MRI lesions, as well as making the claim 
that this population of EVs were “as sensitive as gadolinium-enhanced MRI” for detecting disease 
activity, and that a decrease in vesicle count could be indicative of negative MRI findings (287). 
Despite these bold claims, the findings could not be replicated in vitro and were criticized for being 
premature speculation not supported by sufficient evidence (303). However, the findings pointed 
to the presence of factors within the plasma of MS patients that could potentially be used to monitor 
not only disease progression but also response to therapy (304). 
 Within the same line of research, two additional studies investigating the use of EEVs as 
biomarkers in MS were published over the next five years. The first publication explored whether 
CD54+ and CD62E+ EEVs were capable of binding to leukocytes in vitro as well as in whole 
blood from MS patients and healthy controls (292). The main conclusions drawn from the study 
was that CD54+ EEVs were able to: (1) form complexes with monocytes, (2) complex formation 
was TNF-α-dependent, and (3) monocytes were activated (292). The authors also found that the 
presence of CD62E+ EEV-monocyte complexes were increased during periods of disease 
exacerbation compared to periods of disease remittance while the number of CD54+ EEV-
monocyte complexes remained unchanged. This suggested that the use of CD62E+ EEVs would 
be a better biomarker for monitoring MS disease activity (284). The second study explored the use 
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of free CD54+ and CD62E+ EEVs as biomarkers of disease relapse and remittance. To do this, 
plasma from healthy patients, patients in disease remittance, and patients experiencing disease 
exacerbation were applied to BMVECs in vitro and counts of these EEV sub-populations 
measured. Analysis found that CD54+ and CD62E+ EEVs from patients experiencing active 
disease were significantly higher compared to healthy patients and patients under disease 
remittance. Additionally, these two populations were higher than the CD31+ EEV population 
identified previously, indicating that these populations of EEVs may be a more sensitive measure 
in vitro for identifying MS patient status (288). 
 Other types of EVs have been explored as potential biomarkers in MS, including those 
derived from platelets (289), leukocytes (304), and monocytes (304). Platelet activation can be 
determined through the elevated expression of CD62P (P-selectin) and has been hypothesized to 
be secondary to endothelial damage (289). Analysis of control and patient plasma revealed a two-
fold increase in CD41+ platelet-EVs in MS patients, providing a possible biomarker of disease 
progression (289). Additionally, it has been demonstrated that CD45+ leukocyte-EV and CD14+ 
macrophage-EV counts differ significantly between healthy and MS patients (304). In regards to 
other biofluids, analysis of human CSF has revealed the total number of EVs is higher in MS 
patients compared to controls (293). Further subgrouping of EV populations in these samples 
revealed the acute phase of the disease was associated with higher numbers of macrophage-EVs 
than the stable or chronic phases and that these counts correlated linearly with gadolinium-
enhancing MRI findings (293). These results were further supported using EAE animal models, as 
the concentration of macrophage-EVs in CSF reflected the disease course and severity (293).  
 Currently, the identification of EV biomarkers in HD is still very early (305), whereas there 
are currently no biomarkers yet available for ALS (306). Therefore, future research must expand 
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into these additional neurodegenerative diseases. The potential to discovering a pan-EV biomarker 
that could be used across all neurodegenerative conditions is unrealistic given our current 
understandings of the diseases as well as the heterogeneity of each disease. In establishing 
biomarkers, effort must be spent to create a standardized methodology for isolation and 
quantitation of EVs from patient samples before they can be widely used as biomarkers in 
neurodegenerative diseases. However, the ever-expanding field of EV biology holds promise in 
one day using these tiny carriers of information as disease biomarkers. 
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I. Abstract 
 
Astrocytes are the most abundant glial cell type in the central nervous system (CNS) and are known 
to fulfill critical homeostatic functions. Dysfunction of activated astrocytes is also known to 
participate in the development of several neurological diseases. Astrocytes can be uniquely 
identified by expression of the intermediate filament protein glial acidic fibrillary protein (GFAP). 
Herein, we report on the development of a rigorous and sensitive methodology to identify GFAP+ 
exosomes in primary culture using flow cytometry. We then demonstrate that activated astrocytes 
release increased amounts of exosomes in response to treatment with interleukin-1β. Using this 
methodology, we report the identification of GFAP+ exosomes in blood and then use a mouse 
model of inflammatory demyelination, experimental autoimmune encephalomyelitis (EAE), to 
examine whether the abundance of GFAP+ exosomes in blood circulation changes during clinical 
illness. We find a detectable increase in the presence of GFAP+ exosomes in EAE mice when 
compared with non-EAE, control mice. Our data provide a novel perspective on the presence of 
GFAP in blood as it identifies exosomes as potential astrocyte-derived signals within blood. These 
data are complementary to previous clinical studies that reported elevated GFAP protein in blood 
samples from multiple sclerosis (MS) patients during a clinical relapse. These data also reveal the 
existence of a potential systemic role for astrocyte-derived exosomes in CNS conditions involving 
inflammation such as multiple sclerosis. 
Keywords: exosomes, astrocytes, multiple sclerosis, flow cytometry, GFAP 
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II. Introduction 
 Exosomes are small, extracellular, membrane-bound vesicles (50-150 nm in diameter) 
secreted by cells as a means of selective transfer of biologically active materials from one cell to 
another that function as a mechanism of intercellular communication (256, 308-310). The impact 
of exosomes on physiological functions is mediated, at least in part, by the molecular cargo (e.g., 
proteins and RNA) within the exosomes themselves. Recent findings demonstrating transport and 
transfer of proteins and miRNA via exosomes has prompted increased attention on exosomes as 
potential effectors in diseases as well as the potential to assay exosomes as novel biomarkers for 
the diagnosis, prognosis and treatment of disease. 
 Exosomes develop from multivesicular bodies (MVBs), also known as endosomes. These 
MVBs have a single outer limiting membrane (LM) that surrounds multiple luminal vesicles 
(LVs). LVs are formed from the LM by inward budding. This process also enables the 
incorporation of selected membrane proteins onto the surface of the MVBs (311). Intracellular 
MVBs have one of two fates: they can either be fully degraded by the lysosomes, or they are 
shuttled to the plasma membrane where they fuse and release LVs. It is the release of LVs into the 
extracellular space when these vesicles are called ‘exosomes’ (209). Formation and shedding of 
exosomes can be regulated by intracellular calcium levels (312, 313) or released constitutively, but 
release can also be stimulated by inflammatory stimuli.  
 Within the central nervous system (CNS), exosomes are released by all cell types, including 
neurons, microglia, oligodendrocytes, astrocytes, and neural stem cells (282, 314-316). The 
contents of exosomes differ depending on cell of origin and pathological setting. For instance, 
oligodendrocyte exosomes contain myelin proteins unique to oligodendrocytes (314) and 
microglial exosomes contain proteins common to immune cells(316). Uptake of exosomes by 
immune cells is a novel and potentially important mode of antigen transfer for MHC presentation 
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that can promote T cell activation (311, 317, 318). These findings indicate that exosomes are 
potential mediators of intercellular responses to inflammation and autoimmunity in CNS diseases 
(310, 314, 319). 
 Exosomes are uniquely identified by several proteins, namely, the tetraspanin proteins CD63 
and CD9, lipid raft-associated proteins, including flotillin-1, the heat shock protein HSPA8, and 
the GTP binding protein EEF2, as well as internal, endosomal markers such as Alix and 
Tsg101(230). While the contents of exosomes can also vary based on the cell of origin, exosomes 
routinely contain proteins, peptides, mRNA, and/or miRNA(203). Exosomes released from one 
cell can fuse to another 'target' cell through a non-classical active endocytotic process regulated by 
the lipid raft protein, caveolin-1(320). Since exosomes are released from virtually all eukaryotic 
cell types, their cell-of-origin can also be identified by retained cell-phenotype specific 
markers(209), which makes exosomes potentially useful as sentinels for CNS function in 
pathophysiology. 
 In this study we have focused on the emerging role of activated astrocytes as mediators and 
dynamic participants in a growing number of neurological diseases(321-326). To investigate the 
source and identity of exosomes, we have developed and validated a rigorous methodology to 
identify astrocyte-derived exosomes in biological samples. We also demonstrate the utility of our 
method by identifying astrocyte-derived exosomes in the circulating blood of mice and also report 
elevated detection of these astrocyte-derived exosomes in the blood of mice in an animal model of 
inflammatory demyelination. We hypothesize that these astrocyte-derived exosomes relay 
systemic signaling related to disease and therefore represents a potentially important biomarker of 
CNS function. The detection of astrocyte exosomes in blood also suggest that astrocytes may exert 
a much broader impact on homeostatic and pathogenic regulation of signaling pathways on other 
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cells during disease, 
III. Materials and Methods 
 
Animals and Experimental Autoimmune Encephalomyelitis. All procedures involving animals 
were conducted with approval from the Institutional Animal Care and Use Committee at the 
University of Connecticut School of Medicine and in accordance with guidelines set forth by the 
National Research Council of the National Academies Guide for the Care and Use of Laboratory 
Animals. Mice used in this study were included wildtype C57BL/6 (strain #000664) and GFAP-
Cre mice (JAX strain #024098). To induce experimental autoimmune encephalomyelitis (EAE) 
wild-type C57BL/6 mice (6-8 weeks old) were immunized with a 1:1 ratio of myelin 
oligodendrocyte glycoprotein (MOG35-55,  AnaSpec Inc.) dissolved in deionized water and 
complete Freund’s adjuvant (CFA, Sigma) containing 0.5 mg of Mycobacterium tuberculosis 
H37RA (Difco Laboratories: BD Diagnostics), as previously described(327). The MOG-CFA 
emulsion was administered subcutaneously (s.c.) into the flanks of the hind-limbs (300 µg/mouse). 
On days 0 and 2, pertussis toxin (PTX, List Biological) was injected intraperitoneally (i.p.) (500 
ng/mouse). Weights and clinical scores were recorded daily. The following grading scheme was 
used to score clinical signs of disease severity: 0, no clinical signs; 0.5, distal tail limpness; 1, full 
tail atony; 2, hindlimb paresis; 3, unilateral hindlimb paralysis; 4, bilateral hindlimb paralysis; 5, 
moribund. Blood was collected at peak clinical illness. 
 
Primary Glial Cultures. Cultures were generated from cerebral cortices of neonatal C57BL/6 
mouse pups (P0-P3) using a neural tissue dissociation kit (Miltenyi Biotec), as previously 
described(328). Cells were plated into T75 flasks. The purity of each culture was confirmed and 
consistent with previous reports of 90-97% GFAP+ cells(328), as verified by 
immunocytochemistry (ICC) for GFAP for astrocytes (1:500, Sigma-Aldrich) and Iba-1 for 
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microglia (1:1000, WAKO). Cells were grown to 70-80% confluence, washed two times with PBS 
and incubated for 24 h in serum-free media (Dulbecco’s modified eagle medium, 1% Pen-strep, 
Gibco) or in the presence of 10 ng/mL of IL-1β (Peprotech). Cell culture conditioned media (CCM) 
was collected after 24 h, spun at 3000 x g for 15 minutes at room temperature, and stored at -80°C 
until use. 
 
Blood collection and Exosome Isolation. Blood was collected from CFA or EAE animals at pre-
and peak clinical illness while under deep isoflurane anesthesia using a 1 ml syringe that had been 
flushed with 0.5 M EDTA (Fisher Scientific). Exosome isolation workflow from blood samples is 
shown in Fig 3A. Blood volumes collected ranged from 300-500 µl/animal. Blood was centrifuged 
at 2000 x g for 15 min at room temperature and the upper plasma layer was drawn off. Plasma was 
centrifuged at 1500 x g at room temperature and the supernatant drawn off. Plasma samples were 
then subjected to a differential ultracentrifugation protocol for exosome isolation which were 
confirmed by electron microscopy, western blotting and flow cytometry. Briefly, plasma was spun 
at 12,000 x g for 30 min at 4°C. The supernatant was collected and run through a 0.22 µm spin 
column (Millipore) at 12,000 x g for 4 min at room temperature. Filtrate was collected and equal 
amounts were ultracentrifuged at 118,000 x g for 90 min at 4°C. The supernatant was removed 
and the exosome pellets were re-suspended in 100 µl of sterile, 0.22 µm filtered PBS(-) and stored 
at -80°C until use. All samples were validated by electron microscopy. 
 
Exoquick-TCTM Precipitation. ExoQuickTM precipitation was carried out according the 
manufacturer’s instructions (System Biosciences) and experimental workflow is depicted in Fig 
1A. Briefly, 3 mL of conditioned media was mixed with 0.6 mL of ExoQuick-TCTM solution by 
inverting the tubes several times. The samples were left to incubate overnight at 4°C then 
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centrifuged twice at 1500 x g for 30 and 5 min, respectively, in order to remove the supernatant. 
The supernatant was discarded and the pellet was re-suspended in 100 µL of 0.22 µm-filtered 
PBS(-) and stored at -80°C until use. 
 
Electron microscopy imaging. For negative staining, 15 µl drops of exosomes (in PBS) were 
adsorbed onto activated copper grids with carbon coating (Electron Microscopy Sciences) for 15 
min, washed by dabbing the grid onto three drops of deionized water, and stained with 1% uranyl 
acetate (Electron Microscopy Sciences) for 1 min. Grids were imaged under a Hitachi H-7650 
transmission electron microscope. For immunogold labeling, 15 µl of isolated exosomes were 
adsorbed onto activated nickel grids with carbon coating for 15 min, Grids were then transferred 
to 100 µl drops of PBS and washed twice for 3 min each. Following the PBS wash, grids were 
transferred to 100 µl drops of a PBS/50 mM glycine solution and washed four times for 3 min 
each. Grids were then blocked for 10 min on 100 µl drops of blocking buffer (1% BSA in PBS). 
Grids were then incubated for 30 minutes at room temperature on 30 µl drops of primary antibody 
against TSG101 (1:10 dilution in 1% BSA; Genetex) and GFAP (1:10 dilution in 1% BSA; 
Millipore and Novus Biologicals). Grids were washed on 100 µl droplets of PBS three times for 5 
min, blocked in 1% BSA for 5 min, and incubated with the appropriate secondary antibody 
conjugated with 10 nm gold particles or 15 nm gold particles (Electron Microscopy Sciences; 1:15 
dilution in blocking solution) for 30 minutes. Grids were washed three times for 5 min in PBS 
followed by successive deionized water washes and counter-stained with 15 µl of 1% uranyl-
acetate for 1 min. Excess uranyl-acetate was removed by gently blotting the grids and left to air 
dry before imaging under a transmission electron microscope. Scanning electron micrographs were 
performed on astrocyte in cultures that were fixed in 2.5% gluteraldehyde, post-fixed using 
osmium tetroxide and then dehydrated using ethanol and processed by critical point drying. Cells 
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were then spatter-coated with gold palladium and visualized using a JOEL Scanning EM (JOEL 
USA Inc.). 
 
Western blot analysis. Exosome preparations were lysed in RIPA buffer (with protease inhibitor 
cocktail; Sigma) and separated by SDS-PAGE. Proteins were transferred to nitrocellulose and 
immunoblotted using unconjugated antisera against CD63 (GeneTex), GFAP (Sigma) or TSG101 
(GeneTex) that were then visualized by HRP-conjugated secondary antisera using 
chemiluminescence (ECL; Amersham). 
 
Flow cytometry. Flow cytometric analysis on exosome surface markers was performed at the 
UConn Health flow cytometry core. CD63 (PE anti-mouse; 1:100; Biolegend), GFAP (Alexa Fluor 
647 anti-mouse; 1:50; BD Biosciences), and TSG101 (FITC anti-mouse; 1:50; Lifespan 
Biosciences) were added to sterile, 0.22 µm-filtered PBS (1x, pH 7.4) and spun at 10,000 x g at 
4°C for 30 min to remove protein aggregates from the staining material. Supernatants were 
transferred to fresh 0.2 mL PCR tubes and a 10 µl aliquot of exosome suspension was added. Tubes 
were vortexed before being placed in a 37°C incubator for 60 min. Stained samples were then 
transferred to round-bottom polystyrene tubes and analyzed using a Becton Dickinson (BD) FACS 
Aria-II with a 130 µm nozzle and 10 PSI. Samples were run at the lowest flow rate to ensure the 
most focused core stream until approximately 10,000 single events (based on a 1:1 ratio of side 
scatter (SSC) pulse height to pulse area) were captured. Threshold was set based upon SSC at the 
minimum value of 200 in order to remain unbiased for fluorescence particle detection. Noise was 
determined by running the diluent (0.22 µm-filtered PBS) until ~500-1000 “noise events” were 
captured. This was considered the background signal for the instrument. For analysis of exosomes, 
a minimum of 10,000 events were captured and sorted for subsequent electron microscopy 
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analysis. The detector voltage for Alexa Fluor 647 was set such that unlabeled EVs gave a signal 
that was 2x the robust standard deviation of the "noise events" to clearly distinguish the sample 
contents from the diluent and background signal from the instrument. This was determined by the 
cytometer baseline report from BD Cytometer Setup and Tracking software. Reference beads of 
known sizes (Spherotech, Nano Fluorescent Size Standard Kit; #NFPPS-52-4K) were also used to 
determine instrument performance the day’s experiment as outline in section 3.1. Analysis and 
gating was performed using BD FACS Diva software and FlowJo V10.2. 
 
Statistical Analyses. Experiments were performed in quadruplicate technical replicates for each 
of at least three biological replicates per condition. Comparisons between treatments were made 
using Student’s t-test or repeated measures ANOVA with significance indicated where 
appropriate. Data are presented as mean±SEM using scatter plots to demonstrate data distribution 
within each treatment group. The null hypothesis for all experiments was P<0.05. 
  
IV. Results 
 
3.1 Identification of astrocyte exosomes in primary cultures.  
 
 To establish the identity of exosomes from astrocytes in more complex biological fluids, we 
first collected serum-free media from primary astrocytes in culture in order to benchmark the 
approach and reagents under these defined conditions. Exosomes were collected and then analyzed 
by transmission electron microscopy, which revealed negatively stained exosome-like double 
membrane vesicles with size ranges between 50-150 nm, with a stereotypical cup-shaped 
morphology (Fig 1B). The identity of these extracellular vesicles as exosomes was then confirmed 
by immunogold labeling with the exosome marker TSG101, in conjunction with the astrocyte 
marker, glial fibrillary acidic protein (GFAP) (Fig 1C). Together, these histomorphological 
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features confirmed the collection of exosomes from the astrocyte-conditioned media.  
 We next sought to determine whether flow cytometry could also be adopted as a means to 
reliably identify exosomes in media samples conditioned by primary astrocytes in culture. Flow 
cytometry analysis of exosomes is presently considered a highly desirable, widely accessible 
technology by which to assess the presence of small vesicles, however, the standardization of this 
method for small particle analysis is still in development with no final consensus on the exact 
method to use. A significant limitation of this analysis remains the resolution of size using forward 
angle light scatter (FALS) to trigger a particle “event” on the flow cytometer. Due to their small 
size, extracellular vesicles cannot be distinguished using a traditional forward scatter signal 
detector or photodiode. Some customized and specialized instrumentation uses a more sensitive 
photomultiplier tube for FALS (Stoner et al. 2016), however not all labs have access to such 
instrumentation. On the other hand, side angle light scatter (SSC) and fluorescence are both 
detected using the more sensitive photomultiplier tube (PMT) which allows for resolution of low 
signals such as those produced by small vesicles with respect to the background electronic “noise” 
of the instrument. Taking advantage of these detectors, we set the cytometer to trigger events based 
on the lowest possible setting for SSC and subsequently examined the fluorescence of any particle 
that registered above the noise of the instrument for the given fluorescence detector. Noise was 
determined by acquiring a sample of the media used to dilute the vesicles (FIG 1D). The 
instrument performance for this detection method was determined using a set of yellow-fluorescent 
nano-calibration beads on each experimental day to ensure detection of a 200 nm particle (Fig 1E). 
Although polystyrene bead particles do not have the same refractive index as lipid vesicles for the 
generation of SSC, this test ensured the instrument was at least capable of detecting small particles 
above noise. Another caveat to the use of flow cytometry for small particle detection is the 
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possibility of larger aggregates of particles ("swarm detection"), where several vesicles were 
detected simultaneously (220). To reduce this possibility, all exosome samples were run both 
undiluted and diluted to ensure the fluorescence intensity of the signal remained constant. In 
addition to the dilution of the sample, each exosome sample was run simultaneously with an 
unstained sample, a sample allowed to react with an isotype control Ab, and a sample which only 
contained antibody with dilution media. This strategy then enabled us to discern the labeled 
exosome signal from aberrant signal from unbound antisera and also non-specific binding of Ab 
to exosomes (Fig 1F). Using this step-wise approach we identified exosomes bound to Abs specific 
for the astrocyte marker GFAP as well as canonical exosome markers TSG101 and the tetraspanin 
protein, CD63 (Fig 1F). 
 
3.2 Increased astrocyte exosome release in response to IL-1β. 
 
 We next tested whether our methodology could be used to identify changes in exosome 
release. Previous work has shown that IL-1β is a potent inducer of exosome release. We began by 
examining astrocytes using scanning electron microscopy to determine if membrane 
perturbations/projections, associated with extracellular vesicle release in other cell types could be 
observed in astrocytes. In untreated astrocytes (Fig 2A), the plasma membrane was observed to 
have many long, sinewy projections. In contrast, shortly after treatment with IL-1β, the cell surface 
of astrocytes was noticeably different with numerous bulbous protrusions which resemble 
microblebs (Fig 2B), which reflect intracellular budding events consistent with the process of 
exosome release from exocytosis of MVBs (Gyorgy et al. 2011). This subcellular structural 
response was then associated with a measurable increase in the abundance of exosomes into the 
cell culture media (Fig 2C-G). To test if our flow cytometry approach could be used to identify 
exosomes release from astrocytes activated by IL-1β we assayed the proportion of exosomes 
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released into the conditioned media collected 24 hours after treatment. IL-1β treatment 
significantly increased the abundance of CD63+ particles smaller than 220 nm (exosomes) (Fig 
2C, P<0.001). The proportion of exosomes released by astrocytes was also increased (Fig 2D, 
P<0.01), and we confirmed the exosomal origin of these extracellular vesicles using a second 
marker Tsg101, which also identified a significant increase in response to IL-1β treatment (Fig 
2E, P<0.05). We further validated the identity of increased exosomes as having been derived from 
astrocytes by determining the relative increase in the proportion of GFAP+/CD63+ (Fig 2F, 
P<0.01) and GFAP+/TSG101+ exosomes (Fig 2G, P<0.05). Thus, we confirmed the utility of all 
three markers of astrocyte-derived exosomes (GFAP, CD63 and TSG101) and determined that 
these markers exhibited remarkable concordance between each marker in terms of its magnitude 
of increase in response to IL-1β treatment. Once again, for each exosome isolate tested, we verified 
by TEM the appropriate size class of extracellular vesicles collected from each sample (data not 
shown).  
 
3.3 Identification of astrocyte exosomes in peripheral blood samples.  
 
 The objective of developing a validated approach to identify exosomes from primary 
astrocytes conditioned media was to be able to apply this approach to more complex biological 
fluids. Interestingly, the astrocyte marker protein GFAP has been reported to be found in blood 
from patients suffering from a number of neurodegenerative diseases including Alzheimer’s, ALS, 
and multiple sclerosis (329, 330). Therefore, we hypothesized that GFAP identified in blood 
samples may indicate the presence of astrocyte-derived exosomes. This would suggest that 
astrocyte-derived exosomes are present in peripheral circulation.  
 To test this possibility, we collected blood samples from naïve C57BL/6 mice and isolated 
exosomes from blood plasma using a differential centrifugation protocol (331). Exosomes isolated 
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by this method (Fig 3A) were analyzed by TEM to determine if the vesicles present had all the 
characteristics of exosomes we observed in our conditioned media samples. Negative staining 
confirmed a distinctive cup-shaped morphology of the double membrane vesicles and size class 
consistent with exosomes, ranging from 50-150 nm size range, in these blood plasma samples (Fig. 
3B). Immunogold labeling of exosomes with the astrocyte marker GFAP identified astrocyte-
derived exosomes in these samples from peripheral blood (Fig. 3C).  
 To address whether these GFAP-positive exosomes in blood were indeed derived from 
astrocytes in the CNS and not from other peripheral tissues that have been suggested to be 
immunoreactive for GFAP(330), we collected blood samples from CRE recombinase mice in 
where the transgene was under the control of the mouse GFAP promoter (B6.Cg-Tg(Gfap-
cre)73.12Mvs/J)(332). CRE mRNA expression in these mice is limited to the brain and spinal cord 
whereas no CRE expression is detected in peripheral tissues (data not shown). Blood plasma 
samples were collected and the exosome pellet subjected to western blot analysis for the exosome 
marker CD63, as well as astrocyte specific markers GFAP and the transgene product, CRE protein. 
This western blot analysis confirmed both expression of exosome marker, CD63 (Fig. 3D), as well 
as the astrocyte markers GFAP (Fig. 3D) and the gene product of the transgene, CRE (Fig. 3E). 
Together, these findings confirmed that GFAP+ exosomes present in peripheral blood circulation 
of naÏve adult mice were of astrocytic origin. 
  
3.4 Elevated astrocyte-derived exosomes in blood from clinically affected EAE mice. 
 We next examined whether the amount of astrocyte exosomes in peripheral blood changed 
during course of clinical disease in a model of a neurological disease. To test this, we used the 
same strain of C57BL/6 mice for which we derived our primary glial cultures, and immunized 
adult mice to induce EAE using myelin oligodendrocyte glycoprotein (MOG) peptide as described 
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above. This model of inflammatory demyelination induces a robust, reproducible, and predictable 
CNS demyelination that is used to model the immune-mediated pathology of multiple sclerosis. 
In this set of experiments, mice immunized with MOG35-55 peptide, or given an equal volume of 
CFA, were monitored daily for signs of clinical illness and at the peak clinical disability (Fig 3F), 
Blood was collected from mice either one week following immunization with MOG, or at the peak 
of clinical disability (Day 16 post immunization (Fig 3F). Blood samples from CFA-treatment 
groups were time-matched to either 7 or 16 day time points (Fig 3G,H) Exosome samples were 
then analyzed using flow cytometry to determine the abundance of GFAP+ exosomes in the EAE 
group when compared to CFA controls. Flow cytometry identified increased a low abundance of 
GFAP+ exosomes in all samples and the relative abundance in CFA-treated animals did not differ 
from MOG-immunized animals 7 days post injection (Fig 3G; n=4-6/group). In contrast, analysis 
of GFAP+ exosomes from blood of EAE mice taken during peak clinical disability (Day 16) 
revealed a significant increase in the relative abundance of GFAP+_exosomes in EAE mice when 
compared with time-matched CFA-only treated controls (Fig. 3H). Taken together, these data 
indicate that neuroinflammation associated with EAE was associated with increased presence of 
astrocyte-derived exosomes in the blood. 
   
V. Discussion 
 
 Accumulating evidence indicates that astrocyte dysfunction contributes to the pathogenesis 
of several prevalent neurodegenerative diseases(333-336), including Alzheimer's disease(337), 
amyotrophic lateral sclerosis (ALS)(338), Parkinson's disease(339, 340), Huntington's 
disease(341-343), Alexander's disease(333), and multiple sclerosis(335, 344, 345). Alterations in 
astrocyte function are also reflected in their exosome function. For instance, motor neuron death 
in ALS is non-cell autonomous and results from toxic secreted factors from astrocytes(346-349). 
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Exosomes collected from SOD1 mutant astrocytes have been found to contain the mutant SOD1 
protein, that is transferred into cultured motor neurons when the exosomes fuse(282). Exosome-
mediated transfer of apoptotic proteins also provides a potential mechanism for glial cell death 
Alzheimer's disease(319). The contents of astrocyte exosomes are unknown, but given the 
important physiological roles for astrocytes in neural development(350-352), myelination(344, 
353), synaptic transmission(354, 355), neurovascular coupling(356, 357), regulation of CNS 
infections(358-361) and inflammation(327, 362-364). The context of astrocyte activation in 
disease has lead to proposed phenotype classification with "A1" pro-inflammatory and "A2" anti-
inflammatory states(135, 137, 365-368). Our in vitro experiments using primary astrocytes in 
culture indicate that the abundance of exosomes can be increased in response to IL-1β, which is 
may be indicative of an "A1" state, whereas our in vivo findings may reflect activation but perhaps 
a mix of A1 and A2 states. Nevertheless, our approach to study exosomes from astrocytes may be 
applied to qualify the exosomal components related to these different activation states. Our 
findings demonstrate that astrocytes respond to pro-inflammatory conditions by increasing the 
release of exosomes. Our new validated protocol for detecting astrocyte-derived exosomes in 
conditioned media has also enabled us to assay astrocyte-derived exosomes in more complex 
biological samples (i.e. blood plasma).  
 In this study, we focused on the potential utility of identifying astrocyte exosomes as they 
may relate to study of their function in primary culture and analysis of these extracellular vesicles 
in blood, by applying our methods to an animal model of multiple sclerosis (MS). As mentioned, 
MS is a progressive, demyelinating neurodegenerative disease characterized by development of 
autoreactive T cells, CNS demyelination, and chronic astrogliosis. A number of studies suggest 
that reactive astrocytes contribute heavily to the disease process of demyelination(143, 369, 370). 
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The interplay between the central nervous system and the immune system in the development and 
progression of MS, and in particular the potential role of astrocytes as regulators of T cell activities 
in the CNS raises intriguing questions about the many ways in which astrocyte dysfunction may 
contribute to pathology in this disease(134, 371). Importantly, how these systems counter-regulate 
during the course of disease is a matter currently under investigation.  
 Our findings are the first to identify a potentially new and precise process through which 
the CNS and immune systems may interact: the release of activated, A1-type astrocyte (GFAP+) 
exosomes into the blood may indicate a previously unrecognized, wide-ranging influence of CNS 
astrocytes on systemic physiology in disease. Our findings also identified GFAP positive 
exosomes in the peripheral circulation of mice and increased levels of circulating exosomes in the 
mouse model of multiple sclerosis, EAE. This suggests that astrocytes may exert a much broader 
impact on homeostatic and pathogenic regulation of signaling pathways on other cells during 
disease. While we have not determined whether these changes reflect an alteration in the 
physiological function of exosomes released constitutively versus in response to inflammation, we 
would hypothesize, based on the known function of astrocytes in disease models, that the content 
and function of exosomes would mirror the (patho)physiology of the CNS. For this reason we 
would propose that a potential development from these findings would be the identification of 
specific content markers from within these exosomes that could be used as a biomarker to monitor 
the state of the CNS in health or disease.  
 Experimental evidence for a contributing role of exosomes to the progression of multiple 
sclerosis is currently limited, yet studies identifying the presence of extracellular vesicles in 
numerous body fluids including cerebrospinal fluid (285), blood (287), and urine (372). The 
findings suggest that monitoring of CNS-derived extracellular vesicles, including exosomes, may 
 78 
offer utility for monitoring disease progression and/or responsiveness of MS patients to therapies. 
For instance, Minager et al. observed an increase in endothelial derived microparticles in the 
plasma of MS patients during a relapse that showed a subsequent reduction to control levels during 
remission (287). Exosomes have also been investigated for use as a potential therapeutic to 
stimulate remyelination in MS patients as evidenced by the identification of micro-RNA (miRNA) 
species within the cargo of exosomes that can improve remyelination. This evidence is based off 
the finding that exosomes isolated from interferon-γ stimulated rat bone marrow derived dendritic 
cells containing miRNA-219, which is capable of increasing baseline myelination, reducing 
oxidative stress, and improving remyelination in rats following a lysolecithin demyelinating injury 
(373). These exosomes could also be administered intranasally to rats to improve myelination. 
Beyond a potential therapeutic use of exosomes in MS, there is evidence for their use as diagnostic 
markers in patients receiving treatments. miRNA species have been detected in the blood and urine 
of MS patients undergoing natalizumab therapy (372).  
 The aforementioned findings provide additional future avenues of investigation for the 
potential of astrocyte-derived exosomes in peripheral blood circulation in a wide variety of 
neurological conditions in which changes in astrocytes have been implicated. Currently, exosomes 
are often viewed as passive players: a reflection of the development and progression of numerous 
neurodegenerative diseases. Yet, recent studies provide compelling evidence for an active, 
participatory role for exosomes, including astrocyte-derived exosomes, in chronic 
neurodegenerative diseases. Astrocyte-derived exosomes have already been implicated in 
contributing to the progression and pathogenesis of amytrophic lateral sclerosis (ALS)(120, 336), 
Alzheimer’s(336), and Parkinson’s(336). In each of these neurodegenerative diseases, astrocyte 
exosomes were shown to carry the mutant version of superoxide dismutase-1 enzyme(282), 
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amyloid precursor protein(374), and alpha-synuclein(300), respectively. However, there has been 
no definitive evidence for a role of astrocyte exosomes in contributing to the pathogenesis of 
multiple sclerosis. This is perhaps due to evidence for an active and dual-role of astrocytes in MS 
pathogenesis. It is known that astrocytes play diverse roles in CNS development and disease, but 
in MS, specifically, astrocytes garner attention for their potential to enhance immune responses 
through expression of major histocompatibility complex (MHC) class I and class II molecules(375, 
376) and activation of CD8+ and CD4+ T cells(377-379). Conversely, astrocytes may also elicit 
neuroprotective functions: release of anti-inflammatory molecules (i.e., TGF-β), supporting 
oligodendrocyte regeneration, and facilitating repair of the blood-brain-barrier (120). 
Understanding the precise function of astrocytes may be revealed by the exosomes they shed in 
response to CNS injury. Future experiments should consider the cargo of astrocyte exosomes and 
their potential functional impact. One of our hypotheses is that the effect of astrocyte exosomes is 
a function of time. It could be that early on in the disease process astrocyte exosomes have a 
negative role in modulating the immune response, which results in the demyelinated lesions and 
relapses commonly observed with MS. As the immune response lessens and patients enter 
remission, astrocyte exosomes could have a positive role in modulating the recovery of the lesions 
vis-à-vis remyelination. Future studies will be required to better understand this interesting dual-
role of astrocyte exosomes in the disease process.  
 Presently, the cause of multiple sclerosis is not known. Our finding of elevated numbers of 
astrocyte-exosomes in peripheral circulation during homeostasis and during disease creates a 
potentially interesting avenue of study into better understanding the disease process. These 
findings provide a new perspective by which we may better understand this disease and potentially 
develop new approaches to monitor the course of and understand the pathophysiology of diseases 
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like multiple sclerosis.  
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VI. Figures 
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Figure 3-1: Identification and characterization of a flow cytometry methodology to identify 
astrocytic exosomes in media from primary astrocyte cultures. (A) Work-flow scheme of 
exosome isolation from primary culture conditioned media. (B) Negative stain electron 
micrographs of exosomes isolated from media using a commercially available kit which allows 
for rapid isolation and purification of exosomes (C) Electron micrographs of astrocyte-derived 
exosomes in media verified using immunogold electron microscopy against the exosome marker 
TSG101 (15 nm gold-particle) and astrocyte marker GFAP (10 nm gold particle). (D) The diluent, 
phosphate-buffered saline, was analyzed by the flow cytometer prior to any exosome analysis to 
determine the background noise of the machine prior to each exosome sample. (E) Yellow-
fluorescent calibration beads of different known nanometer (nm) sizes were used to identify both 
the threshold for detection of the flow cytometer prior to the analysis of exosome samples and the 
relative location of that particle size class. (F) Exosome were stained with anti CD63, anti-GFAP 
and anti-TSG101 (right panels) or corresponding isotype controls (left panels). Serial dilutions for 
each antisera were performed and compared to the isotype-matched control for each, to determine 
the optimal dilution that would provide the best signal-to-noise ratio for flow cytometric analysis. 
Scale bars in B,C = 100nm. 
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Figure 3-2: Quantitative increase in detection of astrocytic exosomes in media from primary 
astrocyte cultures following treatment with IL-1β. Scanning electron micrographs of astrocytes 
under control conditions (A) and 1 hour after IL-1B-stimulation (B). Magnifications in A&B are: 
6500x,left panel, and 10000x, right panel). Note (arrows) the membrane perturbations resulting 
from cytokine stimulation that have been associated with the process of extracellular vesicle 
release (in B). (C-G) Analysis of astrocyte-derived exosomes from primary glial cultures using 
flow cytometry using antibodies against CD63 (C), GFAP (D),and Tsg101 (E) show elevated 
detection of events (exosomes) following IL-1β treatment. Additional analyses of GFAP+/CD63+ 
(F) and GFAP+/Tsg101+ (G) labeling confirmed an increased relative abundance of astrocyte-
derived (GFAP+) exosomes (CD63+ or Tsg101+). Control (vehicle) treated cultures ("Naive") had 
an identifiable amount of exosomes in conditioned media but the proportion of exosomes detected 
was markedly increased in response to IL-1β treatment. Significance is indicated where: *,P<0.05; 
**,P<0.01, ***,P<0.001 t-test. Scale bars in A,B = 1 µm 
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Figure 3-3: Identification and characterization of astrocyte-derived exosomes in blood 
plasma from mice and increased detection of GFAP+ exosomes in blood from mice during 
EAE. (A) Work flow scheme for exosome isolation from blood plasma.  (B) Electron micrographs 
of extracellular vesicles isolated from peripheral blood plasma revealed prototypic "cup-shaped 
morphology" of the appropriate size class for exosomes. (C) Immunogold electron microscopy 
using anti-GFAP and gold particle conjugated secondary antisera (15 nm) identified exosomes 
from blood plasma that were astrocyte-derived. Scale bars: size bar, A = 100 nm; B =100 nm. (D) 
Western blotting analysis of the EM exosome preparations from blood plasma analyzed in A, B 
confirmed detection of exosomal (CD63) and astrocytic markers (GFAP) in the exosome pellet. 
(E) Validation of astrocytic origins using expression of CRE recombinase protein in blood plasma 
as measured by western blotting from exosome preparation from GFAP-CRE transgenic mice. 
Samples were diluted (as indicated) to demonstrate that antibody reactivity was serially diminished 
which supports the specificity of the antibody binding. E' represents a shorter exposure of the blot, 
while E'' represents a longer exposure time which were needed to visualize CRE-reactive bands in 
the more diluted samples, respectively. The CRE-reactive bands were of the same molecular 
weight as observed in the most concentrated sample. (F) Clinical EAE scores of myelin 
oligodendrocyte glycoprotein (MOG) immunized C57BL/6 mice (n=6) and control (CFA 
inoculated; n=4). Mice were euthanized one week following immunization or time point of peak 
clinical illness (day 16). Euthanization of CFA control animals were time-matched for either day 
7 (arrow) or day 16 (arrow), respectively, for blood collection and blood plasma exosome isolation. 
(G) Flow cytometry analysis of blood plasma exosomes from EAE and control (CFA) mice at a 
pre-clinical disease timepoint (day 7), and (H) at the time of peak clinical illness (Day 16). GFAP+ 
exosomes in blood of control mice did not differ in preclinical disease (Day 7) MOG immunized 
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mice, whereas a notable increase in the detection of astrocyte-derived exosomes in blood plasma 
was observed in mice at the time of peak clinical illness in EAE. Significance is indicated where: 
(F) ****, P<0.0001, 2-way ANOVA; (H) **, P=0.0031; t-test. 
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I. Abstract 
Extracellular vesicles (EVs) are emerging as potent mediators of intercellular communication with 
roles in inflammation and disease. In this study, we examined the role of extracellular vesicles 
from blood plasma (pEV) in an experimental autoimmune encephalomyelitis mouse model of 
central nervous system demyelination. We determined that pEVs induced a spontaneous relapsing-
remitting disease phenotype in MOG35-55-immunized C57BL/6 (R/R-EAE) mice. This modified 
disease phenotype was found to be driven by CD8+ T cells and required fibrinogen in pEVs. 
Analysis of pEVs from relapsing-remitting multiple sclerosis (RRMS) patients also identified 
fibrinogen that was uniquely citrullinated. Together, these data suggest that fibrinogen in pEVs 
contributes to the perpetuation of neuroinflammation and relapses in disease.  
 
 
Significance Statement 
In this novel report, we show that fibrinogen, identified by proteomics to be present in blood 
plasma extracellular vesicles (EVs), is sufficient and required for autoimmune-mediated relapsing 
disease in a murine model of multiple sclerosis (MS). Unique to this model is that plasma EVs 
induced CD8-mediated disease and hence models human MS, which is not typically the case for 
experimental murine models. Strikingly, an analysis of human plasma EVs identified unique 
citrullination motifs of fibrinogen in MS patient samples thereby providing a compelling 
association between our experimental findings and autoimmunity in human MS. Our new system 
unveils a major biomedical breakthrough by linking EVs with relapsing disease using cutting edge 
proteomics, and solid preclinical human data.  
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II. Introduction 
Successful translation of discovery research into clinical efficacy is often hampered by the 
authenticity of experimental animal models to faithfully recapitulate disease pathogenesis. For 
instance, study of the adaptive immune responses in experimental autoimmune encephalomyelitis 
(EAE) mouse models of multiple sclerosis (MS) have become a basis for our understanding and 
pre-clinical therapeutic development (96). Yet, the immunological phenotype of MS patients 
notably differs from mice in which immunization with myelin peptides induce robust T-cell 
responses (380). Significant attention on CD4+ T cells in MS has been supported by both GWAS 
identified risk susceptibility genes for MS and the central role of CD4+ T cells in many EAE 
mouse models (99, 381, 382). However, CD4+ T cells do not underlie the clinical disease course 
in human MS patients and interrogation of infiltrating lymphocyte subtypes in MS patients has 
revealed a predominance of CD8+ T cells over CD4+ T cells (117, 383, 384). The repertoire of 
CD8+ T cells in the CSF of MS patients, and to a lesser extent in blood, reflects elevated levels of 
CD8+ T cells also identified in lesions within the CNS (385). These findings have led to important 
questions on the etiology of CD8+ T cell responses, their potential roles in mediating clinical 
exacerbations, and how to model this immune response in mice (386). The enrichment of CD8+ T 
cells in MS suggests a critical effector role for CD8+ T cells in this disease, but the inherent 
difficulty in modeling spontaneous CD8+ T cells in EAE models has hindered rigorous study of 
encephalitogenic CD8+ T cells in the context of autoimmunity and MS.  
Extracellular vesicles (EVs) have emerged as a potent mediators of immunity (387) with 
the potential for affecting CD8+ T cell activity. EVs are nano-sized membrane particles released 
by cells that represent an evolutionarily conserved mode of intercellular communication (388). 
Interest in EVs has been stimulated by their emerging roles in disease and potential use as 
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prognostic biomarkers (205). Interest in EVs is driven by recent experimental evidence 
demonstrating EV-directed intercellular communication contributes to cancer, inflammatory, 
neurological and autoimmune diseases (389). Hence, EVs represent a rapidly evolving field with 
potential to understand complex diseases. In particular, the innate cellular complexity and relative 
inaccessibility of the CNS offer the potential for EV biology to provide better understanding and 
insight to monitor inflammatory and degenerative changes (261). Plasma EVs (pEVs) have also 
been reported to reflect features of inflammation in human neurological diseases such as 
Alzheimer’s disease(390), Parkinson’s disease (300), and MS (284). Yet, how pEVs may 
contribute to the autoimmunity of multiple sclerosis has not been elucidated.  
In this study, we assessed the functional impact of pEVs on neuroinflammation and clinical 
disability in a mouse model of CNS demyelination. We report that pEVs from naive C57BL/6 
mice when transferred into mice with active EAE results in a distinct spontaneous relapsing-
remitting EAE phenotype characterized by a prominent contribution of CD8+ T cells. Proteomic 
analysis identified a causal role for fibrinogen in pEVs inducing the unique clinical and 
immunological phenotype in this pEV-EAE model. We characterize the pEV-EAE approach as 
representing an authentic immunological system with utility for disease modeling and 
understanding the etiology of CD8+ T cell responses in disease relapses in MS which may have 
implications for translation of experimental findings to human patients. 
III. Materials and Methods 
 
Animals. Mice used in this study included wild-type male C57BL/6 (strain #000664, The 
Jackson Laboratory)) and Fib-/-mice(391) (kindly provided by Jay Degen).  All procedures 
involving animals were conducted with prior approval from the Institutional Animal Care and Use 
Committees at the University of Connecticut School of Medicine and the University of California, 
San Francisco in accordance with guidelines set forth by the National Research Council of the 
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National Academies Guide for the Care and Use of Laboratory Animals. Mice were housed under 
a 12:12 light/dark cycle, 55 ± 5% relative humidity, and a temperature of 20 ± 2°C with access to 
standard laboratory chow and water ad libitum. They were housed in social groups of a maximum 
of 5 mice each in standard mouse housing cages and bedding. 
Experimental Autoimmune Encephalomyelitis (EAE). was induced in wild-type 
C57BL/6 mice (8-12 weeks old) by immunizing with a 1:1 ratio of myelin oligodendrocyte 
glycoprotein (MOG35-55, AnaSpec Inc.) dissolved in deionized water and complete Freund’s 
adjuvant (CFA, Sigma) containing 0.5 mg of Mycobacterium tuberculosis H37RA (Difco 
Laboratories: BD Diagnostics), as described in previous studies (162, 307). The MOG-CFA 
emulsion was administered subcutaneously (s.c.) into the flanks of the hind-limbs (300 µg/mouse). 
On days 0 and 2, pertussis toxin (PTX, List Biological) was injected intraperitoneally (i.p.) (500 
ng/mouse). Weights and clinical scores were recorded daily by an experimenter blinded to 
experimental treatment of subjects. Clinical signs of disease severity were: 0, no clinical signs; 
0.5, distal tail limpness; 1, full tail atony; 2, hind-limb paresis; 3, unilateral hind-limb paralysis; 4, 
bilateral hind-limb paralysis; 5, moribund. 
Blood collection and pEV Isolation. Whole blood from naïve C57BL/6 mice was 
collected while under deep isoflurane anesthesia using a 1 ml syringe that had been flushed with 
0.5 M EDTA (Fisher Scientific). Whole blood was collected from confirmed Fib-/-and 
Fib+/+littermates, and were coded for genotype and blinded prior to pEVs isolation and EAE 
experiments. Injected isolated pEVs into any single recipient were equal to the blood volume of 
one mouse (1.46 mL) whole blood. Whole blood was centrifuged at 2000 x g for 15 min at room 
temperature and the upper plasma layer was drawn off. Plasma was centrifuged at 1500 x g at 
room temperature and the supernatant drawn off. Plasma samples were then subjected to a 
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differential ultracentrifugation protocol for extracellular vesicle isolation as previously described 
(307). Briefly, plasma was spun at 12,000 x g for 30 min at 4°C. The supernatant was collected 
and equal amounts were subjected to ultracentrifugation at 150,000 x g for 90 min at 4°C. The 
supernatant was removed and the extracellular vesicle pellets were re-suspended in 150-200 µl of 
sterile, 0.22 µm filtered PBS and stored at -80°C until use. All samples were validated by electron 
microscopy. 
CD8 and Isotype antibody injections. 500 µg of either αCD8 (InVivoMAb anti-mouse 
CD8 [Lyt 2.1, Clone: 116-13.1 (HB-129)], Bio X Cell, West Lebanon, New Hampshire) or αCD8-
isotype antibody (InVivoMAb mouse IgG2a Isotype control [Clone: C1.18.4], Bio X Cell, West 
Lebanon, New Hampshire) in sterile PBS was injected intraperitoneally into pEV-injected MOG-
EAE mice at peak clinical EAE and 5 days later. 
Cytometry by time of flight. Brains were obtained from vehicle or pEV-injected MOG-
EAE mice 10 days following injections. Brains were digested with a collagenase/DNase solution 
and lymphocytes isolated using a 70%/40% percoll gradient. Each sample (n = 4) was labeled with 
Cell-ID cisplatin to identify live and dead cells and subsequently barcoded with Cell-ID Pd 
barcoding kit [all mass cytometry (CyTOF) reagents are from Fluidigm, San Francisco, CA]. The 
four samples were permeabilized with methanol and incubated with Fc receptor blocking solution 
and a 31 heavy-metal conjugated antibody panel, including seven signaling markers, as previously 
described20. DNA was labeled using Cell-ID Intercalator-Ir. The samples were spiked with 
normalization beads and analyzed by a mass cytometer (HELIOS, Fluidigm) at Jackson 
Laboratories (Farmington, CT). The data were debarcoded using the Fluidigm Debarcoder v1.04. 
A single-cell and live-cell gate were identified in each sample. The samples were downsampled to 
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ensure equal numbers of cells per sample for ViSNE analysis (FlowJo, FlowJo, LLC, Ashland, 
Oregon) (392).  
Electron microscopy imaging. For negative staining, 20 µl drops of pEVs (in PBS) were 
adsorbed onto activated copper grids with carbon coating (Electron Microscopy Sciences) for 15 
min, washed by dabbing the grid onto three drops of deionized water, and stained with 1% uranyl 
acetate (Electron Microscopy Sciences) for 1 min. Grids were imaged under a Hitachi H-7650 
transmission electron microscope. For immunogold labeling, 20 µl of isolated pEVs were adsorbed 
onto activated nickel grids with carbon coating for 15 min. Grids were then blocked for 10 min on 
100 µl drops of blocking buffer (1% NGS in PBS). Grids were then incubated for 60 minutes at 
room temperature on 25 µl drops of primary antibody against fibrinogen (1:10 dilution in 1% NGS; 
Dako; catalog ID: A0080) and flotillin-1 (1:10 dilution in 1% NGS; BD Transduction; Clone 
18/Flotillin-1). Grids were washed on 100 µl droplets of PBS three times for 5 min, blocked in 1% 
NGS for 5 min, and incubated with the appropriate secondary antibody conjugated with 15 nm 
gold particles or 10 nm gold particles (Electron Microscopy Sciences; 1:15 dilution in blocking 
solution) for 60 minutes, respectively. Grids were washed three times for 5 min in PBS followed 
by successive deionized water washes and counter-stained with 25 µl of 1% uranyl-acetate for 1 
min. Excess uranyl-acetate was removed by gently blotting the grids which were then left to air 
dry before imaging under a transmission electron microscope. 
Human Blood Samples. Plasma samples were obtained from a total of three patients with 
MS and three healthy, non-diseased controls, after patient consent (Supplementary Table 5). This 
study was approved by the Office for the Protection of Research Subjects at University of Illinois 
at Chicago and the Department of Defense Human Research Protection Office. All patients with 
MS were diagnosed with RRMS and one with secondary progressive MS according to the revised 
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McDonald criteria. At the time of blood collection, all patients with RRMS were in remission. All 
but one patient with MS were under specific MS medication. Three milliliters of blood was 
collected in tubes with 0.5M ethylenediaminetetraacetic acid (EDTA; BD, Franklin Lakes, NJ). 
Blood was pre-spun at 1500 x g for 15 mins at room temperature to isolate plasma. Plasma was 
then spun at 12,000 x g for 30 minutes to remove contaminating microvesicles and flash-frozen on 
dry ice until extracellular vesicle isolation.  
Western blot analysis. pEV preparations from either mouse or healthy human subjects or 
RRMS patient plasma were lysed in RIPA buffer (with protease inhibitor cocktail; Sigma) and 
separated on a pre-cast 12% Gel (Bio-Rad) by SDS-PAGE. Proteins were transferred to 
nitrocellulose and immunoblotted using unconjugated antisera against fibrinogen (Dako; catalog 
ID: A0080; 1:2500), fibrinogen alpha chain (Abnova; catalog ID: H00002243-D01P; 1:1000), and 
the EV marker flotillin-1 (BD Transduction; Clone 18/Flotillin-1; 1:500) that were then visualized 
by HRP-conjugated secondary antisera (Vector Laboratories; 1:1000-5000) using 
chemiluminescence (Clarity Western ECL; Bio-Rad). Images were captured using a ChemiDoc 
XRS+ imaging system (Bio-Rad). Human plasma plasminogen-depleted fibrinogen (EMD 
Millipore #341578) or mouse plasma plasminogen-depleted plasma fibrinogen (abcam #ab92791) 
(100 ng) were used as positive controls for the identification of fibrinogen chains on pEVs. 
In solution Protein Digestion. Extracellular vesicle pellets were resuspended in 1XRIPA 
buffer containing Halt Protease Inhibitor Cocktail (ThermoScientific Prod# 87786). Samples were 
homogenized by sonication, and cleared by centrifugation at 14,000 rpm, 4°C, 10 min on a desktop 
centrifuge.  Proteins were extracted by Chloroform/Methanol precipitation using established 
protocols.  Protein pellets were dissolved and denatured in 8M urea, 0.4M ammonium bicarbonate, 
pH 8. The proteins were reduced by the addition of 1/10 volume of 45mM dithiothreitol (Pierce 
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Thermo Scientific #20290) and incubation at 37ºC for 20 minutes, then alkylated with the addition 
of 1/10 volume of 100mM iodoacetamide (Sigma-Aldrich #I1149) with incubation in the dark at 
room temperature for 20 minutes. The urea concentration was adjusted to 2M by the addition of 
water prior to enzymatic digestion at 37°C with LysC (Wako, #125-05061) for 4 hours, then 
trypsin (Promega Seq. Grade Mod. Trypsin, # V5113) for an additional 16 hours. Protease:protein 
ratios were estimated at 1:50. Samples were acidified by the addition of 20% trifluoroacetic acid, 
then desalted using C18 MacroSpin columns (The Nest Group, #SMM SS18V) following the 
manufacturer’s directions with peptides eluted with 0.1% TFA, 80% acetonitrile. Eluted sample 
was speedvaced dry and dissolved in MS loading buffer (2% aceotonitrile, 0.2% trifluoroacetic 
acid). A nanodrop measurement (Thermo Scientific Nanodrop 2000 UV-Vis Spectrophotometer) 
determined protein concentrations (A260/A280). Each sample was then further diluted with MS 
loading buffer to 0.08µg/µl, with 0.4ug (5µl) injected for LC-MS/MS analysis.  
LC-MS/MS on the Thermo Scientific Q Exactive Plus. LC-MS/MS analysis was 
performed on a Thermo Scientific Q Exactive Plus with a Waters nanoAcquity UPLC system, 
using a Waters Symmetry® C18 180µm x 20mm trap column and a ACQUITY UPLC PST (BEH) 
C18 nanoACQUITY Column 1.7 µm, 75 µm x 250 mm (37ºC) for peptide separation. Trapping 
was done at 5µl/min, 97% Buffer A (100% water, 0.1% formic acid) for 3 min. Peptide separation 
was performed at 330 nl/min with Buffer A: 100% water, 0.1% formic acid and Buffer B: 100% 
acetonitrile, 0.1% formic acid. A linear gradient (90 minutes) was run with 3% buffer B at initial 
conditions; 5% B at 1 minute; 35% B at 50 minutes; 50% B at 60 minutes; 90% B at 65-70; and 
back to initial conditions at 71 minutes. MS was acquired in profile mode over the 300-1,700 m/z 
range using 1 microscan; 70,000 resolution; AGC target of 3E6; and a full max ion time of 45 ms. 
MS/MS was acquired in centroid mode using 1 microscan; 17,500 resolution; AGC target of 1E5; 
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full max IT of 100 ms; 1.7 m/z isolation window; normalized collision energy of 28; and 200-
2,000 m/z scan range. Up to 20 MS/MS were collected per MS scan on species with an intensity 
threshold of 2E4, charge states 2-6, peptide match preferred, and dynamic exclusion set to 20 
seconds. 
LC-MS/MS on the Thermo Scientific Orbitrap Fusion. LC-MS/MS analysis was 
performed on a Thermo Scientific Orbitrap Fusion equipped with a Waters nanoAcquity UPLC 
system utilizing a binary solvent system (Buffer A: 100% water, 0.1% formic acid; Buffer B: 100% 
acetonitrile, 0.1% formic acid). Trapping was performed at 5µl/min, 97% Buffer A for 3 min using 
a Waters Symmetry® C18 180µm x 20mm trap column. Peptides were separated using an 
ACQUITY UPLC PST (BEH) C18 nanoACQUITY Column 1.7 µm, 75 µm x 250 mm (37ºC) and 
eluted at 300 nl/min with the following gradient: 3% buffer B at initial conditions; 5% B at 5 
minutes; 20% B at 90 minutes; 35% B at 125 minutes; 97% B at 130 minutes; 97% B at 135 min; 
return to initial conditions at 136-150 minutes. MS was acquired in the Orbitrap in profile mode 
over the 300-1,500 m/z range using quadrupole isolation, 1 microscan, 120,000 resolution, AGC 
target of 4E5, and a maximum injection time of 60 ms.  MS/MS were collected in top speed mode 
with a 3s cycle time on species with an intensity threshold of 5E4, charge states 2-8, peptide 
monoisotopic precursor selection preferred. Dynamic exclusion was set to 30 seconds. Data 
dependent MS/MS were acquired in the Orbitrap in centroid mode using quadrupole isolation 
(window 1.6m/z), HCD activation with a collision energy of 28%, 1 microscan, 60,000 resolution, 
AGC target of 1E5, maximum injection time of 110 ms.   
Peptide Identification. Data was analyzed using Proteome Discoverer software v2.2 
(Thermo Scientific). Data searching is performed using the Mascot algorithm (version 2.6.0) 
(Matrix Science) against the SwissProtein database with taxonomy restricted Homo sapiens. The 
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search parameters included tryptic peptides with up to 3 missed cleavages, 10 ppm precursor mass 
tolerance and 0.02 Da fragment mass tolerance, and variable (dynamic) modifications of 
methionine oxidation, carbamidomethylated cysteine, deamidated asparagine or glutamine, and 
citrullination of arginine. Normal and decoy database searches were run, with the confidence level 
set to 95% (P < 0.05). Scaffold (version Scaffold_4.8.7, Proteome Software Inc., Portland, OR) 
was used to validate MS/MS based peptide and protein identifications. Peptide identifications were 
accepted if they could be established at greater than 95.0% probability by the Scaffold Local FDR 
algorithm. Protein identifications were accepted if they could be established at greater than 99.0% 
probability and contained at least 2 identified peptides.   
Quantitative Real-time Polymerase Chain Reaction (qRT-PCR). Total RNA was 
isolated from saline-perfused unfixed whole brain tissue using TRI Reagent (Sigma) according to 
the manufacturer’s protocol. cDNA was amplified using the iScript kit (BioRad) and qPCR was 
performed using specific validated primer pairs for Cxcl10 and Ccl2 (Integrated DNA 
Technologies, Coralville, IA) and using the SsoAdvanced™ Universal SYBR® Green Supermix 
(BioRad) according to the manufacturer’s protocol. Target cDNA was amplified and analyzed by 
the CFX Connect™ Real-Time PCR Detection System (BioRad). Primers for β-actin were used 
to assess the general expression level of the housekeeping gene among samples. The relative 
expression of target RNA was calculated using the comparative cycle threshold analysis (ΔΔCT). 
 Statistical analysis. Data were analyzed by two-way ANOVA with uncorrected Fisher’s 
LSD post-hoc test or non-parametric Mann-Whitney U-test as indicated using GraphPad Prism 
version 7 for MAC OS X (GraphPad Software, La Jolla, California, USA). Differences were 
considered significant when P < 0.05. Data are presented as mean ± s.e.m. 
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IV. Results  
Plasma EVs induce spontaneous relapses in EAE mice. 
EAE immunization in mice on the C57BL/6 background induces a robust and consistent 
monophasic clinical disease course mediated by a prominent CD4+ lymphocyte activation (386, 
393). pEVs isolated from stored red blood cell units have been found to bind to monocytes and 
induce pro-inflammatory cytokines, which boosts CD4+ and CD8+ T cell responses in vitro (315). 
Additionally, EVs are capable of augmenting pre-existing inflammatory responses in vivo (394). 
Whether and how pEVs can augment the neuroinflammatory events in EAE have not been 
previously examined. To determine if pEVs can augment the inflammatory response in EAE mice, 
we first isolated and confirmed the presence of EVs from mouse blood-plasma. The purity of 
isolated pEVs was verified by electron microscopy (EM), an approach to validate EVs we have 
used previously (307) (Figure 1B). To determine the effect pEVs have on the EAE disease course, 
MOG-EAE immunized mice received a single injection of pEVs at the time of peak clinical 
disability (Figure 1A). We found that pEV-injected MOG-EAE mice developed a worsened 
pattern of EAE with clinical disability characterized by spontaneous relapses with remissions 
(R/R) that were not observed in control EAE subjects (Figure 1C-D). These findings are consistent 
with a previous report that permutations of MOG-EAE in C57BL/6 mice can evoke a relapsing-
remitting disease phenotype (395). 
  
pEVs induce CD8+ T cells. 
To determine whether and how pEVs evoked neuroinflammatory changes within the CNS of EAE 
mice, we next analyzed expression of the Fb-inducible chemokines Ccl2 and CXCL10 in brain 
tissues of R/R EAE (pEV administered) mice during a first relapse event. Ccl2 and CXCL10 levels 
were found to be increased in the brain during relapse of pEV-treated R/R mice (Figure 2A). Since 
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these two chemokines are known to promote Fb-induced T cell and macrophage recruitment into 
the CNS (396), we examined the composition of the immune cell infiltrates in the brains of pEV-
administered EAE mice during a relapse. To explore this question, we applied an unbiased survey 
of immune cells by using flow cytometry by time of flight (CyTOF) and applied T-distributed 
stochastic neighbor embedding (t-SNE) analysis of all labeled CNS immune cells. This approach 
identified a specific increase in CD3+/CD8+ T cells in pEV-administered, R/R-EAE mice (Figure 
2B). Since autoimmunity in MOG35-55-EAE mice is typically driven by CD4+ T cells (162), we 
next established the contribution of CD8+ T-cells to R/R EAE mice by immunodepletion of CD8+ 
cells from R/R mice (Figure 2C). Administration of anti-CD8 antisera was found to prevent the 
relapsing activity phenotype in response to pEV administration in treated mice (Figure 2D-E). 
Anti-CD8 antisera did not affect disease in control EAE mice not given pEVs (data not shown), 
nor did an Ig-matched control antisera change disease exacerbation activity in treated R/R mice 
(Figure 2D-E). Hence, pEVs induced a robust CD8+ T cell response which was required for the 
relapsing-remitting phenotype in treated EAE mice. 
  
Fibrinogen mediates relapse inducing action of pEVs. 
Proteomic analysis of the pEVs was performed using the two-dimensional protein 
fractionation platform (PF-2D; Figure 3A). Proteome lab identification of enriched fractions were 
interrogated by LC/MS/MS. These fractions identified a limited number of candidate factors 
(Supplementary Table 1), which included fibrinogen alpha chain (FGA). As a candidate pEV 
factor, fibrinogen (Fb) was of particular interest because Fb deposition occurs with vascular 
leakage and promotes T cell recruitment, CNS demyelination, and axonal damage (397). 
Immunoblotting and EM confirmed pEV expression of the EV marker, flotillin-1 (Figure 3B), and 
co-localization of Fb in the pEVs (Figure 3C). To determine whether Fb was a necessary cargo of 
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pEVs to induce R/R in MOG-EAE mice, pEVs were collected from fibrinogen knockout (Fib-/-) 
mice and wild-type littermate (Fib+/+) controls (Figure 3D). When the Fib-/- pEVs were 
administered to MOG-EAE mice, these mice did not develop any change in typical EAE course 
(Figure 3E-F), while administration of Fib+/+ pEVs induced the R/R clinical phenotype with 
disease exacerbation as observed with other wildtype pEV donor blood samples (Figure 3E-F). 
These data determined that Fb in pEVs was required to induce a pattern of spontaneous relapsing-
remitting activity in EAE mice. 
  
Citrullinated Fb Identifies EVs from MS Patients. 
  To determine whether pEVs from human blood, including in MS patients, also contained 
Fb we performed a proteomic analysis of pEVs from non-diseased subjects and patients with 
RRMS. LC-MS/MS of the pEVs also identified Fb in human pEVs (Supplementary Table 2). 
We validated isolation of pEVs and confirmed the presence of Fb in these pEVs by 
immunoblotting using plasma-isolated human Fb as a positive control (Figure 4A and B). No 
apparent differences in the Fb peptide fragments were identified when comparing RRMS with 
control pEV samples, however, recent studies have pointed to post translational modifications of 
peptides through citrullination as a disease-associated process (62, 398, 399). Indeed, citrullination 
has been reported to promote autoimmunity, and in response to demyelination, citrullination of 
myelin peptides has been recently shown to initiate neuroinflammation (62). To address this 
possibility, we then performed LC-MS/MS analysis on an Orbitrap mass spectrometer to identify 
post-translational modifications on peptides of the same pEV samples. This identified a short list 
of citrullinated peptides in pEVs (Supplementary Table 3). Of these, citrullinated Fb peptide 
sequences were identified on alpha, beta, and gamma chains in RRMS and control pEV samples 
(Supplementary Figure 1 and Table 4). An analysis of citrullinated peptide motifs in Fb of 
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RRMS and control pEV samples revealed preferential modification of arginine preceding proline 
unique to the RRMS pEVs samples (Figure 4C). This motif may represent a difference in the 
recognition and/or potential functional impact of these citrullinated motifs of Fb related to RRMS 
disease (400). Moreover, our data extend upon previous findings in other human diseases by 
having identified citrullinated peptides of Fb in pEVs. 
 
V. Discussion 
 
In this report, we demonstrate a novel mechanism to induce and study encephalitogenic 
CD8+ T cells in the widely used MOG35-55-EAE mouse model of multiple sclerosis (MS). We 
show that plasma extracellular vesicles (pEVs) administered at the time of peak of clinical disease 
in mice with active EAE resulted in the development of a unique phenotype of spontaneous 
relapsing-remitting disease - a clinical feature not generally observed in this MOG35-55-EAE mouse 
model. Using a top down-proteomic approach to interrogate pEVs we identified fibrinogen as the 
component of pEVs responsible for inducing CD8+ T cell-mediated spontaneous relapses.  
CD8+ T cells are the predominant T cell subtype found within active lesions in RRMS 
patients, which are posited to be the primary cellular mediators of CNS injury during relapse events 
(401, 402). Despite this, the most widely studied mouse model of MS, MOG35-55-EAE, induces a 
prominent CD4+ T cell driven disease (96). While this model has provided insights into the 
immunology of MS, salient features such as the paucity of CD8+ T cells in this model has limited 
detailed exploration on the role of CD8+ cells as a key feature of the human disease. Our study 
applied CyTOF analysis to identify which immune cells in pEV-treated MOG35-55-EAE mice 
contributed to the relapsing phenotype and determined that immunoblocking of the striking 
elevation in the proportion of CD8+ T cells in the pEV-treated mice prevented the relapsing 
phenotype. These data further strengthen the argument for CD8+ T cells as a driver of relapsing-
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remitting disease. Moreover, the widespread elevated expression of MHC class I antigens in active 
lesions in acute and chronic MS (115, 118) suggest a pervasive role for cytotoxic CD8+ T cells in 
the MS brain that can ostensibly be better studied using the pEV-R/R-EAE model. Of particular 
interest to demyelination, oligodendrocyte-specific autoreactive CD8+ T cells have been found to 
lyse oligodendrocytes in vitro and CD8+ T cells from MS patients have been found to secrete toxic 
factors, such as lymphotxin, that are damaging to oligodendrocytes (403, 404). While our data 
would place pEVs as a proximal cause of encephalitogenic CD8+ T cells in disease, future studies 
will be needed to resolve the identities and specificities of the CD8+ T cell population(s) resulting 
from the initiation of CD8-mediated immunity in this model.  
Based on our findings, we would also postulate that pEV-associated fibrinogen may 
contribute to HLA class I linkage disequilibrium and increased susceptibility for autoimmunity, 
which has been identified in human MS (405). Our data support accumulating evidence that now 
point to fibrinogen as an important disease-related trigger for the development of an 
encephalitogenic adaptive immune response associated with CNS demyelination with striking 
features similar to those observed in human MS (396, 397). Fibrinogen is known to be a critical 
component of the blood coagulation cascade that is cleaved into fibrin to stabilize the formation 
of blood clots. Interestingly, due to its unique molecular structure, binding sites on fibrinogen for 
receptors expressed by CNS cells, such as astrocytes, oligodendrocytes, and microglia, and for 
proteins (e.g., TGFβ and Aβ) have been found to regulate key nervous system functions (397, 406).  
The study of extracellular vesicle (EV) biology and function is a rapidly growing field of 
active research. EVs are membrane-bound organelles that are released from tissues containing a 
diverse array of molecular cargo (e.g., RNA, protein, and metabolites) (407). EVs have been 
identified in many different biofluids, including blood-plasma. The functional relevance of the 
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release of EVs into circulation in the broad contexts of health and disease is an area of continuing 
investigation. Our data suggest that pEV function is at least partially reliant upon its EV proteome. 
Indeed, previous studies have shown RNA and even protein transfer as a consequence of 
intercellular communication by EVs (407). Within the specific context of active inflammatory 
disease, pEVs when administered to mice with active MOG35-55-EAE led to the development of a 
spontaneous relapsing phenotype that was dependent upon pEV fibrinogen. This result is 
consistent with previous findings that fibrinogen-deficient plasma when injected into the brain 
parenchyma did not induce an encephalitogenic T cell response when compared to fibrinogen-rich 
plasma (396). That pEVs are a source of fibrinogen and also potent effectors of fibrinogen's effects 
on inflammation under disease conditions is a striking but not unexpected result. In cancer, MHC 
class I and MHC class II complexes on EVs have been shown to carry tumor or pathogenic peptides 
that can stimulate CD4+ or CD8+ T cells directly, as well as indirectly through interactions with 
APCs (389). Additionally, EVs can transfer both antigens and signals to APCs to promote their 
activation into immunogenic APCs (261). Given the diverse potential effector functions of EVs on 
the activity of the immune cells, our findings provide additional evidence for pEVs as modulators 
of the autoimmune response in multiple sclerosis. While we have determined that pEV fibrinogen 
can evoke CD8+ T cells, we do not know the precise mechanism by which EV-associated 
fibrinogen achieves this effect. Moreover, our analysis of pEVs from healthy human donors and 
from MS patients would suggest that in patients, it is not fibrinogen itself but its post-translational 
modification (PTM) that makes this protein of particular interest in the context of autoimmunity 
and immune-mediated pathology in MS. 
Identification of citrullinated peptides in pEVs, in the context of the dysregulated immune 
responses in MS, support a growing awareness that PTMs contribute to the repertoire of peptides 
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in the plasma (pEV) and represent an important component to understand disease pathogenicity 
(Figure 4D). Citrullination, or deimination, is a process by which a guanidine group of arginine is 
hydrolyzed to a ureido group and ammonia that produces a deiminated amino acid called citrulline 
(408, 409). This PTM of arginine to citrulline is carried out by a family of five citrullinating 
enzymes known as peptidylarginine deiminases (PADs). Of the PAD family proteins, PAD2 and 
PAD4 are present in brain tissue and upregulated in the CNS in EAE (408, 409). Additionally, a 
number of PAD substrates have already been identified, including GFAP (410), MBP (411), 
nuclear proteins (412), and CXC chemokine family members (413). The robust fibrinogen-evoked 
CD8+ T cell response is analogous to a delayed-hypersensitivity type III response similar to the 
role of citrullinated fibrinogen in promoting T cell driven autoimmunity in rheumatoid arthritis 
(RA) (414, 415). While there are known MHC II susceptibility genes in MS that point towards 
CD4+ T cells as the master driver of disease progression, it is well known that CD4+ T cells prime 
CD8+ T cells for effector function (115). Therefore, the presence of citrullinated fibrinogen 
peptides under normal, non-diseased conditions would not itself be antigenic, however, if present 
during active inflammation, the antigenicity of citrullinated peptides may serve to exacerbate the 
inflammatory response. Specifically, citrullination results in the loss of a positive charge which 
can evoke altered secondary and tertiary structures of the proteins, which can result in enhanced 
antigenicity of peptides (408, 409). Our data would implicate PAD enzyme functions in the 
citrullination of fibrinogen in pEVs in MS which may contribute, by yet undefined mechanisms, 
to foster development of autoreactive CD8+ T cells driving neuroinflammation.  
In summary, our findings on the elucidation of pEV-mediated CD8-driven immunity in 
EAE provides unique insights into plausible mechanisms by which endogenous blood factors can 
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drive encephalitogenic T cell responses in MS. Continued study of this pEV-EAE model may be 
expected to elucidate the etiology of relapse activity in human RRMS (118, 416). 
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VII. Figures 
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Figure 4-1: pEVs induced a spontaneous relapsing-remitting phenotype in wild-type 
C57BL/6 mice during MOG35-55-induced EAE. (A) pEVs isolated from donor mouse plasma 
[were confirmed by transmission electron microscopy shown in (B)], or vehicle were administered 
(i.v.) to EAE mice at peak clinical illness (arrow). (C) Representative clinical EAE disease courses 
in pEV and vehicle-treated mice. (D) Grouped treatment effect over 51-day experimental period 
of vehicle and pEV-treated MOG35-55-EAE mice (n=6/group). Scale bar is 100nm. Values are mean 
± s.e.m., where ****P < 0.0001 and *P < 0.05 calculated by two-way ANOVA with uncorrected 
Fisher’s LSD post-hoc test. 
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Figure 4-2: pEVs induce a CD8+ T-cell response responsible for the development of a 
spontaneous relapsing phenotype in MOG35-55-EAE. (A) Expression of chemokines Ccl2 (n = 
3) and Cxcl10 (n = 3) was significantly up-regulated at time of a spontaneous relapse in the brains 
of pEV-R/R mice. (B) CyTOF analysis of brains of R/R mice identified unique CD8+ T cell 
population. (C) EAE in pEV-treated EAE mice also given αCD8 function blocking antibody or 
isotype antisera, and (D) representative clinical disease courses in individual treated mice, and 
plotted as group (E) (αCD8; n = 8; isotype control, n = 7). Values are mean ± s.e.m., where ****P 
< 0.0001 and *P < 0.05 calculated by two-way ANOVA with uncorrected Fisher’s LSD post-hoc 
test; *P < 0.05 (Mann-Whitney test).  
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Figure 4-3: pEV fibrinogen is necessary to induce a spontaneous relapsing-remitting 
phenotype in wild-type C57BL/6 mice during MOG35-55-induced EAE. (A) Topographic plot 
of proteomic (PF-2D) analysis of mouse pEVs and identified fractions for MS/MS peptide 
identification. Immunoblotting (left) and immuno-EM (right) confirmed EV marker (B) flotillin-
1 (48 kDa) and (C) blood coagulation factor fibrinogen alpha (63.5 kDa), beta (56 kDa), and 
gamma (47 kDa) chain expression on pEVs as confirmed by plasma-isolated murine fibrinogen 
immunoblotting. (b’ and c’) Secondary-only immuno-EM of pEVS. (D) Clinical effect of pEVs 
isolated from Fib+/+ or Fib-/- mouse plasma when injected (i.v.) into MOG35-55 EAE mice at peak 
clinical illness. (E) Representative clinical disease course of individual mice MOG-EAE mice 
administered Fib+/+ or Fib-/- pEVs. (F) Grouped treatment effect data of Fib+/+ pEVs and Fib-/- 
pEV-treated mice (n = 6-9/group). Scale bars are 100nm. Arrows indicate α-fibrinogen and α-
flotillin-1 gold particles. Values are mean ± s.e.m., where ****P < 0.0001, **P < 0.01, and *P < 
0.05 calculated by two-way ANOVA with uncorrected Fisher’s LSD post-hoc test. Fib+/+ denotes 
wild-type littermate mice and Fib-/- denotes fibrinogen knock-out mice. 
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Figure 4-4: Proteomic analysis of pEVs from RRMS patient samples identified a unique 
citrullination peptide motif. Immunoblotting confirmed EV marker (A) flotillin-1 and (B) 
fibrinogen alpha chain on human pEVs (n = 3/condition) as confirmed by plasma-isolated human 
fibrinogen. (C) Motifs of citrullination differed in non-diseased (upper) and RRMS (lower) patient 
pEVs. (D) Proposed model for pEV Fb promoting CD8+ T-cell mediated relapses and 
inflammation associated with CNS demyelination.  
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Chapter 5: Discussion and Future Directions 
 Growing interest into the multifactorial roles of extracellular vesicles (EVs) in health and 
disease has grown almost exponentially over the last 20 years. More specifically, this growing 
interest has spread to understanding EVs in the context of normal brain functioning and during the 
course of neurological diseases and disorders. In my thesis, I explored how EVs could act as a 
biomarker of disease exacerbation in MS and their ability to modulate the disease course. My data 
found that astrocyte-derived EVs are a potential source of biomarkers within the blood that can be 
utilized to track the disease status of MS patients. Additionally, I found that plasma EVs are 
capable of inducing a dramatic relapsing-remitting phenotype via the presence of the blood 
coagulation factor fibrinogen being in close association with these EVs.  
 Although my thesis was focused on EVs in MS, the findings can broadly be applied to a 
variety of CNS disorders where astrocytes and blood-borne factors can influence the disease 
course. Further, interrogating the EVs of other CNS cells, such as microglia and oligodendrocytes, 
may provide a unique approach to understanding the changes that occur in these cells during 
disease and provide new targets for biomarker development.   
 
I. Astrocytes and Exosomes 
 Astrocytes have long been considered part of the “glue” that provides structure to the brain, 
however this passive view of these cells has been challenged over the last 20 years and we now 
know that astrocytes are an extraordinarily dynamic and heterogenous cell population within the 
CNS (417). This is of particular importance in diseases of the CNS as astrocytes can have both 
positive and negative effects in modulating the extracellular environment (348, 362, 418). One 
potential source of extracellular regulators are EVs. A quickly growing field that is encompassing 
all facets and manners of human disease, EVs can induce critical and significant changes in host 
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and target cells to drive or negate pathology (262, 282, 314). However, directly linking the cellular 
source of EVs to pathological or protective responses in vivo is a challenging endeavor due to the 
innate heterogeneity of EVs in biofluids, lack of cell-specific markers that can recognize EVs, and 
disparate methods of isolation and characterization (212, 331, 388).  
 In an effort to tackle these inherent problems in studying EVs, the first part of my thesis 
was directed at establishing a new and reliable method for the isolation and semi-quantitative 
analysis of astrocyte-derived exosomes from both in vitro and in vivo settings (307). For the 
isolation of exosomes in this study I used two, well-established methodologies: the commercially 
available ExoQuick-TC™ precipitation kit and a differential ultracentrifugation protocol (218). It 
should be noted there are limitations to using both of these methods including: (1) incomplete 
isolation of all exosomes, (2) presence of precipitate in isolated fractions, (3) and contamination 
of pellets with cellular debris, proteins, and larger vesicles. However, it is currently impossible in 
the field of EV biology to eliminate all of these caveats, rather the goal is to focus on minimizing 
the potential for contamination. I also employed the use of FACS to semi-quantitatively analyze 
exosomes from culture media and blood-serum. Flow cytometry is a gold-standard for the 
detection and quantification of physical and chemical characteristics of populations of cells or 
particles. Despite this, there are inherent problems in using FACS analysis to quantify exosomes. 
As stated in chapter two, exosomes are nanosized vesicles roughly 50-150nm in size. The 
fluorescence detectors on flow cytometers are designed for the purposes of analyzing cells, which 
can be anywhere from 1 µm to 100 µms in size, with a lower limit of detection at 200 nm (personal 
communication with the director of the Flow Cytometry Core, Evan Jellison). Therefore, to bridge 
this gap, I developed a methodology that would allow for not only the detection of exosomes at 
this lower limit of detection, but also for the semi-quantitative analysis of exosome numbers and 
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the specific isolation of astrocyte-derived exosomes. I used the stereotypical astrocyte marker 
GFAP in tandem with the canonical exosome markers TSG101 and CD63 to (1) determine if 
astrocytes released more exosomes following IL-1β cytokine challenge and (2) if astrocytes 
released more exosomes into peripheral circulation during the EAE disease course. My findings 
of increased exosome release following cytokine challenge and during the peak of clinical 
disability in EAE animals was the first report to my knowledge addressing these questions (307). 
As a note, I will be using EV from this point forward rather than exosome to maintain clarity 
throughout the rest of the discussion.  
 BBB breakdown is a common feature associated with MS, as well as other 
neurodegenerative diseases (419, 420). Astrocyte endfoot processes form close associations with 
the basement membrane of endothelial cells to form the glia limitans, which prevents and regulates 
the free movement of small molecules and cells into the brain parenchyma (421). In EAE, the 
animal correlate of MS, BBB breakdown and leakage has been found to occur (422). In my own 
study, I found that GFAP-positive astrocyte-EVs were readily detected in peripheral circulation in 
EAE and control animals prior to clinical onset but significantly increased at the height of clinical 
disability (307). At the time of publication of this study, we were unsure what role astrocyte EVs 
played in the EAE disease process, if any. However, a study from Dickens et al. two years later 
identified one possible role. In this study, it was observed that intrastriatal administration of IL-1β 
resulted in an increase of EVs in peripheral circulation (423). The authors then isolated plasma 
EVs from these mice and infused them intravenously into recipient mice where they observed an 
ACR in the liver and the transmigration of leukocytes to the brain parenchyma. Since astrocytes 
have an intimate association with the BBB and based on observations that astrocytes release more 
EVs following IL-1β stimulation compared with microglia, the authors infused EVs isolated from 
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IL-1β treated astrocytes in vitro into mice. This resulted in a peripheral ACR and transmigration 
of leukocytes into the brain parenchyma, providing proof-of-concept that cytokine-induced 
astrocyte-EVs are capable of initiating an immune response that seems to be driven by the liver 
(423). This also fits nicely with, and corroborates, my in vitro findings of an increased release of 
EVs from astrocytes treated with IL-1β (307). The identification of an astrocyte-liver-brain axis 
as a form of communication between the CNS is periphery, coupled with my findings of increased 
astrocyte-EVs in EAE points to a larger role of the CNS directing and regulating the immune 
response to brain injury. Pursuing additional mechanisms and investigating other peripheral organs 
where astrocyte-EVs have been found to travel (e.g., lung and spleen (423)) will fill in critical gaps 
in our knowledge and may provide for novel therapeutic targets in treating MS and other 
neurodegenerative diseases with BBB disruption.   
 It has been noted that astrocyte-derived EVs can be detected in peripheral circulation under 
non-diseased conditions since it is well established that BBB breakdown and permeability 
increases under neurodegenerative diseases (420). The dogma surrounding the BBB as a solid 
barrier between the periphery and nervous system would inform us that any EVs released by neural 
cells would be either restricted to the CNS compartment or contained within the CSF. Therefore, 
determining why astrocytes, and potentially other neural cells, release EVs into the peripheral 
circulation under non-diseased conditions is a compelling area for future studies. The use of 
fluorescence reporter mice tagged to known EV proteins has been utilized for not only tracking 
EVs in vivo but also to identify the cellular and tissue-specific localization of specific EV 
populations (423, 424). Using cell-specific fluorescence, then, could be a powerful tool to identify 
the target cells of neural-cell derived EVs (and vice-versa), which could provide compelling 
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evidence of a significant cross-talk between the CNS and periphery in monitoring and regulating 
normal, everyday functioning.  
 However, this should not overshadow the importance of understanding the functional 
consequences of astrocyte-EVs in the healthy CNS. The known roles of astrocytes in maintaining 
normal CNS functioning has been discussed extensively in Chapter 1, however there is a critical 
gap in our knowledge regarding the role(s) astrocyte EVs play in this maintenance. For example, 
I have found that astrocyte-derived EVs promote the differentiation and maturation of rat OPCs, 
whereas EVs derived from astrocytes following IL-1β cytokine challenge inhibit this maturation 
(Figure 5-1). This identifies a potential role for astrocyte EVs in OPC maturation not only in the 
developing CNS, but also following tissue damage and injury. Future studies using state-of-the art 
techniques in fluorescence imaging and microscopy, such as fluorescence resonance energy 
transfer (FRET) or super-resolution microscopy, respectively, could help to identify unique 
populations of astrocyte EVs and their cognate receptors that will allow for a more thorough 
understanding of the functional and mechanistic roles these vesicles play. Additionally, future 
studies analyzing and characterizing the proteomic, RNA, and lipidomic content of astrocyte EVs 
would allow for the development of a detailed EV interactome. The information gathered in this 
astrocyte-EV interactome would give researchers a foundation to develop novel hypotheses to 
elucidate the contribution of astrocyte EVs in maintaining normal brain functioning.   
 The pursuit of discovering biomarkers for tracking and monitoring disease progression is 
an active and growing field. As EVs are readily isolated from many biofluids using non-invasive 
procedures, they are attractive candidates for biomarker discovery (425, 426). The identification 
of astrocyte GFAP in association with EVs in blood from my own work, in addition to the work 
by Dickens et. al. to identify a mechanism of action for these EVs points to the potential future 
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development of GFAP-EVs as a biomarker in MS. However, further steps must be taken to validate 
astrocyte-EVs as biomarkers in this disease. Future studies identifying additional astrocyte 
markers, such as aldehyde dehydrogenase 1 (aldh1l1) or glutamate aspartate transporter (GLAST), 
on EVs and whether the expression of these proteins on EVs changes during the course of disease 
is warranted. One such way to perform this would be to gather blood samples from cohorts of 
healthy and RR-MS patients over a set time span of the disease to monitor changes in GFAP-EV 
levels (or in conjunction with other known candidate astrocyte markers) and correlate any 
identified changes with disease exacerbations (i.e. relapses) or worsening clinical disability. If any 
noticeable patterns were to arise, efforts would have to be made to streamline the isolation and 
characterization of blood EVs. This would entail the design of a rapid, reliable, and reproducible 
method of EV isolation for downstream characterization, as the current gold standard in the field, 
differential ultracentrifugation coupled with density gradient separation, is time-consuming and 
requires specialized pieces of equipment. There are numerous commercially available EV isolation 
kits, however these kits can be cost prohibitive and suffer from insufficient yield, low purity, and 
lack of consistency (427). However, the far bigger issue with using EVs as biomarkers is the 
complete lack of a consensus method for the absolute quantification of EV number from the source 
biofluid. The most widely used quantification method involves the use of a nanoparticle analyzer. 
These instruments use the brownian motion of particles in a fluid to determine the concentration 
and size of EVs in a sample. Despite the ability of these instruments to quantitate the number of 
EVs in a given sample, the machines are costly, require training, and involve extensive calibration 
of the instrument for optimal performance. Therefore, the use of semi-quantitative methods, as 
detailed in my study, could provide an alternative method for detecting changes in EV levels. Flow 
cytometry analysis is currently used as a way to characterize diseases in a clinical setting  (428, 
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429), therefore adapting methodologies developed in biomedical research for use in the clinics 
with access to flow cytometers is an attractive avenue. The field of EV biology is in its infancy, 
however studies extensively characterizing EVs from specific cell types coupled with 
improvements in technologies aimed at quantifying EVs will hopefully one day lead to the first 
EV biomarker to be used in a clinical setting.  
 
II. Plasma EVs and Relapsing-Remitting Multiple Sclerosis  
 There is growing interest into understanding how factors present in blood-plasma 
fundamentally contribute to the immune activation and neurodegeneration associated with many 
neurological disorders. This is due to the significant structural changes that are known to occur at 
the neurovascular interface during active neurological disease, which leads to an influx of plasma 
proteins into the CNS thereby disrupting the homeostasis between the vasculature and the CNS 
(397, 430). One major plasma protein that has been studied for its causal role in MS pathology, as 
well as many other neurodegenerative diseases, has been fibrinogen, which is involved in the blood 
coagulation cascade (397). Briefly, in tissue or vascular injury fibrinogen is enzymatically 
converted by thrombin to fibrin, which forms the basis of fibrin-based blood clots. However, 
fibrinogen is also considered ‘positive’ acute-phase protein, meaning the levels of fibrinogen 
increase in response to systemic inflammation, tissue injury, and various other events (66). This is 
of particular relevance to MS, as increased tissue injury (e.g. BBB breakdown and lesion 
formation) and systemic inflammation are strong drivers of the disease pathology and progression 
(31, 431). In fact, it has already been shown that intracerebral injections of fibrinogen into the CNS 
can promote an autoimmune response with associated demyelination that has pathological 
correlates to the human condition (396). Therefore, understanding how fibrinogen contributes to 
the pathogenesis of MS is an area of active research. 
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 In my own thesis studies, I have found that fibrinogen is associated with EVs isolated from 
blood-plasma (pEVs), and that it is capable of inducing a relapsing-remitting phenotype in an EAE 
mouse model of MS disease (see Chapter 4). However, I was not able to fully elucidate the 
mechanism wherein these pEVs induced the relapsing-remitting phenotype. I had performed 
CyTOF (i.e. mass cytometry) and identified an increase in CD8+ T cells in EAE mice receiving 
pEV injections versus PBS injected controls. This fits with prior findings of increased CD8 T cells 
in RRMS patients (118), however CD8 T cells are a heterogenous population (432) and future 
studies in the lab will need to focus on identifying which population(s) of CD8 T cells are 
responsible for driving these relapses. CyTOF is a powerful tool that can be used to identify unique 
groups or populations of cells and would be indispensable in helping to identify the critical CD8 
population driving the relapses observed in my studies. Additionally, if a group of CD8 T cells 
were shown to be differentially activated in pEV-injected EAE animals, traditional FACS of this 
population followed by RNA-sequencing could allow for a mechanistic understanding of the 
changes in these cells that drives the phenotype. RNA-seq coupled with proteomic analysis could 
then allow for the analysis of critical pathways that drive the positive or negative regulation of 
these cells that could be targeted for therapeutic intervention to dampen their activation.  
 The identification of cellular sources of EVs from complex biofluids, such as plasma, are 
extraordinarily difficult given our current technical limitations and biological understandings in 
regards to EV characterization. However, based on a priorii knowledge, I would estimate a large 
portion of circulating EVs, including fibrinogen-associated EVs, are derived from platelets given 
their critical importance in producing and directing blood clotting (433). However, to my 
knowledge, no attempts at EV characterization of blood-plasma has been performed. Therefore, 
future studies using CyTOF coupled with proteomic, miRNA, and RNA-sequencing analysis of 
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plasma EVs could lead to a more holistic understanding of the make-up of plasma EVs and lead 
to the identification of EVs from other cellular sources. This would be a challenging endeavor and 
may not lead to a full understanding of the complexity of plasma EVs, but given my development 
of a methodology to isolate specific EV populations from blood and the analytical power of mass 
cytometry, findings from such a study could provide a small peek into the representative EV 
populations present in plasma. 
 I have already outlined a need in the first part of my discussion to identify the cellular 
targets of astrocyte-derived EVs. That line of thinking is also applicable to this portion of my thesis 
studies. While it would be impractical, if not impossible, to use transgenic animals to identify and 
track the biodistribution of EVs in peripheral circulation, ex vivo labeling of EVs through pan-
lipophilic dyes is an attractive alternative. This process involves the isolation of EVs from plasma 
followed by labeling with a near-infrared lipophilic dye (DiI; Invitrogen) that can intercalate into 
the membranes of EVs, allowing for in vivo analysis of EV trafficking and biodistribution using 
an in vivo imaging system (IVIS Spectrum In Vivo Imaging system, PerkinElmer) (434). 
Preliminary results from labeling experiments I performed, wherein I intravenously injected DiI 
labeled plasma EVs into a normal wild-type mouse and mouse with active EAE, identified a 
preferential biodistribution of EVs to the brain and liver (Figure 5-2). This is of particular interest 
based on the study I had previously discussed identifying the liver as one potential peripheral organ 
that could be driving immune activation directed at the CNS (423). Further studies using in vivo 
imaging would require extensive immunohistochemical analysis of tissue sections from both the 
brain and liver to identify the preferential trafficking of plasma EVs to tissue-resident cells. These 
studies could also be supplemented with proteomic and genomic analysis of targeted cells to 
identify activity changes in critical pathways known to drive immune activation. Further, in vitro 
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assays of tissue-specific cells, such as ELISA for secreted factors and immunocytochemistry using 
flow cytometry for intracellular production of cytokines and chemokines would provide crucial 
information on how the liver is capable of shaping an immune response that targets the CNS. One 
known receptor for fibrinogen is CD11b/CD18, which is present on macrophages and CNS-
resident microglia (396). Fibrinogen interacting with this receptor is thought to drive the 
autoimmune response observed following intracerebral injection of fibrinogen (396). Future 
studies, however, will need to further investigate whether EV-bound fibrinogen has a similar 
affinity for the CD11b/CD18 receptor or if there is preferential trafficking to other CNS resident 
cells, such as oligodendrocytes, astrocytes, and/or neurons. In regards to astrocytes, it has been 
found that fibrinogen can trigger astrocyte scar formation (435) and that astrocytes can specifically 
take-up and remove fibrinogen (436). However, future studies investigating these aspects in an 
EAE animal need to be actively pursued, as well as investigating whether astrocytes have similar 
capacities in EAE animals following pEV injections.  
 An area of active and growing research is focused on the role of post-translational 
modifications (PTM) as a contributor to inflammation and autoimmunity. PTMs can promote the 
generation of neo-(auto)antigens, which can lead to the generation of an autoimmune response in 
subjects with a pre-disposed reduction in self-tolerance, such as patients with MS and rheumatoid 
arthritis (RA) (30, 437, 438). One such PTM, citrullination, has garnered great interest due to its 
presence in a wide range of inflammatory tissues (438). Citrullination, also known as deimination, 
is the conversion of the amino acid arginine in a protein into the amino acid citrulline through 
enzymes called peptidylarginine deiminases (PADs) (411). As a result, citrullinated proteins can 
become antigenic and lead to the immune system to mount an autoimmune response to these self-
peptides through the production of autoantibodies (411). Citrullinated MBP (439) and GFAP (410) 
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have already been identified as possible antigenic targets in MS that can be readily focused by the 
immune system. Fibrinogen can also undergo citrullination and autoantibodies directed against 
citrullinated fibrinogen has strong diagnostic, predictive, and prognostic value for RA, where it 
has been extensively studied (438). Since citrullination can lead to a strong autoimmune response, 
part of my thesis studies involved PTM analysis of pEVs from healthy and RRMS patients. I found 
that, indeed, fibrinogen is citrullinated in both patients, however there seemed to be a 
conformational shift in the protein structure of pEV-bound fibrinogen that could expose the 
citrullinated peptide making it an antigenic target by the immune system (See Chapter 4). Given 
this finding, it would be necessary in the future to determine if there was generation of 
autoantibodies against citrullinated fibrinogen in these animals, as is observed in RA. If such a 
finding were to occur, then therapeutics directed against citrullinated fibrinogen could be tested in 
EAE animals following pEV injections to determine if this is an effective strategy for dampening 
the immune response I have observed. Additional studies could investigate whether the 
citrullinated peptide sequences in fibrinogen are specific to MS patients versus healthy controls. 
There could be preferential citrullination of targeted fibrinogen sequences in MS patients that 
renders them more susceptible to loss of self-tolerance and the generation of an autoimmune 
response. This is a complex route to take, however, due to the high variability in pathological 
presentation of MS. There is also the concern that citrullination may only be affecting a small 
subset of the overall MS patient population, rendering this line of investigation susceptible to a 
‘fishing expedition’ or chasing a needle in a haystack. Should specific, antigenic fibrinogen 
sequences be identified, generating antibodies to citrullinated peptides could prevent the immune 
system from recognizing these sequences as foreign and lead to a reduction in overall 
inflammatory burden in MS patients. Citrullination occurs as a result of PADs and it has been 
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shown that inhibition of PAD activity prior to the onset or induction of mouse models of 
neurodegeneration and autoimmunity can reverse citrullination and prevent disease activity (440). 
Therefore, investigating PAD activity in pEV-injected EAE mice should be investigated to 
determine if increased expression of these enzyme could be a causative agent in driving the 
relapsing phenotype and, if so, whether therapeutic intervention can abolish the relapsing 
phenotype observed. Further, analysis of PAD activity in the blood of healthy and MS patients 
could be analyzed to determine if increased PAD activity correlates to disease exacerbation or as 
a predicative diagnostic readout of a nascent relapse.  
 
III. Concluding Statement 
 My thesis studies into astrocyte and plasma EVs have shed light on the potential role for 
these vesicles in contributing to the initiation of disease, exacerbation of diseases, and as potential 
diagnostic and therapeutic targets in MS. However, further research and studies, which have been 
outlined, must be performed to better characterize these EVs before the scientific community can 
accept the findings as impactful. I have a strong belief, though, that through innovative thinking 
and elegant experiment design, many of these questions will be answered and further cement a 
place for EVs in the pathology of MS and, hopefully, many other neurodegenerative diseases. 
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Figure 5-1: Astrocyte EVs promote the differentiation and maturation of rOPCs in vitro. 
rOPCs were treated with either constitutively released astrocyte-EVs or IL-1β stimulated 
astrocyte-EVs and differentiation analyzed after 48 hours in vitro. There was a significant increase 
in rOPC differentiation following constitutive astrocyte-EV treatment compared to OPC 
maintenance media. IL-1β stimulated astrocyte-EVs significantly inhibited OPC differentiation 
compared to constitutive astrocyte-EVs and no difference was observed compared to OPC 
maintenance media. Significance as indicated where: **P < 0.01 and ****P < 0.0001, one-way 
ANOVA with Tukey’s multiple comparison test. Values are expressed as mean ± SEM. 
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Fig. 5-2: IVIS imaging of DiR-labeled EVs injected into naïve and MOG-EAE mice. Blood 
plasma EVs were stained with the lipophilic tracer DiR and I.V. injected into naïve or EAE animals 
at peak clinical illness. Imaging of organs three hours following injection showed EVs 
preferentially trafficked to the liver and brain in both naïve (left) and MOG-EAE mice (right).  
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